Compositions and methods for increased protein production in Bacillus licheniformis

Abstract

The present disclosure generally relates to compositions and methods for constructing and obtaining Bacillus licheniformis cells with an increased protein production phenotype. Accordingly, certain other embodiments relate to modified B. licheniformis derived from a parent B. licheniformis cell. Certain embodiments relate to modified B. licheniformis cells comprising a modified rghR locus. Certain embodiments relate to modified B. licheniformis cells with a modified rghR locus and comprising an increased protein production phenotype. In certain other embodiments, modified B. licheniformis cells with a modified rghR locus produce reduced amounts of red pigment. In certain other embodiments, modified B. licheniformis cells comprise an increased protein production phenotype and produce reduced amounts of red pigment.

Description

[Technical field]

[0001] The present disclosure relates generally to the fields of bacteriology, microbiology, genetics, molecular biology, enzymology, industrial protein production, etc. More particularly, the present disclosure relates to compositions and methods for obtaining Bacillus licheniformis strains with increased protein production capabilities.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 886,571, filed Aug. 14, 2019, which is incorporated by reference in its entirety.

[0003] Sequence Listing Reference The contents of the electronic submission of the sequence listing text file entitled "NB41514-WO-PCT_SequenceListing.txt" was created on June 23, 2020, is 316KB in size, and is incorporated by reference in its entirety herein. [Background technology]

[0004] Gram-positive bacteria such as Bacillus subtilis, Bacillus licheniformis, and Bacillus amyloliquefaciens are frequently used as microbial factories to produce industrially relevant proteins due to their excellent fermentation properties and high yields (e.g., up to 25 grams per liter of culture; Van Dijl and Hecker, 2013). For example, B. subtilis is well known for producing α-amylases (Jensen et al., 2000; Raul et al., 2014) and proteases (Brode et al., 1996) required for the food, textile, laundry, medical equipment cleaning, and pharmaceutical industries (Westers et al., 2004). These non-pathogenic Gram-positive bacteria produce proteins (e.g., lipopolysaccharides; LPS, also known as endotoxins) that are completely free of harmful by-products and have been awarded a "Qualified Presumption of Safety" (QPS) rating by the European Food Safety Authority, and many of their products have been awarded "Generally Recognized As Safe" (GRAS) status by the US Food and Drug Administration (Olempska-Beer et al., 2006; Earl et al., 2008; Caspers et al., 2010). Summary of the Invention [Problem to be solved by the invention]

[0005] Therefore, the production of proteins (e.g., enzymes, antibodies, receptors, etc.) in microbial host cells is of particular interest in the field of biotechnology. Similarly, the optimization of Bacillus host cells to produce and secrete one or more proteins of interest is highly important, especially in the context of industrial biotechnology, where small improvements in protein yields are of crucial importance when the protein is to be industrially mass-produced. More particularly, B. licheniformis is a host cell of Bacillus species of high industrial importance, and therefore the ability to modify and engineer B. licheniformis host cells for enhanced / increased protein expression / production is highly desirable for constructing new and improved B. licheniformis production strains. The present disclosure thus relates to a highly desirable and unmet need for obtaining and constructing B. licheniformis cells (e.g., protein-producing host cells) with increased protein production capacity. [Means for solving the problem]

[0006] The present disclosure relates generally to compositions and methods for constructing and obtaining Bacillus licheniformis cells (strains) having an increased protein production phenotype. More particularly, certain embodiments relate to an engineered Bacillus licheniformis cell derived from a parent B. licheniformis cell that contains a native rghR (chromosomal) locus, wherein the engineered cell comprises at least one modification of the rghR locus selected from the group consisting of: (i) an engineered rghR1 gene, (ii) an engineered rghR2 gene, (iii) an engineered rghR1 gene and an engineered rghR2 gene, and (iv) an engineered rghR1 gene, an engineered rghR2 gene, an engineered yvzC gene, and an engineered Bli3644 gene, wherein the engineered cell produces an increased amount of a protein of interest (compared to the parent cell when cultured under identical conditions).

[0007] In certain embodiments, the modified rghR1 gene mutates, disrupts, partially deletes, or completely deletes the encoded RghR1 protein, and / or the modified rghR1 gene comprises a genetic modification that mutates, disrupts, partially deletes, or completely deletes the 5'-UTR and / or 3'-UTR sequences of the rghR1 gene, and the modified rghR1 gene does not express or produce the encoded RghR1 protein.

[0008] In certain embodiments, the modified rghR2 gene mutates, disrupts, partially deletes, or completely deletes the encoded RghR2 protein, and / or the modified rghR2 gene comprises a genetic modification that mutates, disrupts, partially deletes, or completely deletes the 5'-UTR and / or 3'-UTR sequences of the rghR2 gene, and the modified rghR2 gene does not express or produce the encoded RghR2 protein.

[0009] In certain embodiments, the modified yvzC gene mutates, disrupts, partially deletes, or completely deletes the encoded YvzC protein, and / or the modified yvzC gene comprises a genetic modification that mutates, disrupts, partially deletes, or completely deletes the 5'-UTR and / or 3'-UTR sequences of the yvzC gene, and the modified yvzC gene does not express or produce the encoded YvzC protein.

[0010] In certain embodiments, the modified Bli3644 gene mutates, disrupts, partially deletes, or completely deletes the encoded Bli3644 protein, and / or the modified Bli3644 gene comprises a genetic modification that mutates, disrupts, partially deletes, or completely deletes the 5'-UTR sequence and / or the 3'-UTR of the Bli3644 gene, and the modified Bli3644 gene does not express or produce the encoded Bli3644 protein.

[0011] Thus, in certain embodiments, the modified B. licheniformis cell comprising at least one genetic modification at the rghR locus comprises a modified rghR1 gene. In other embodiments, the modified B. licheniformis cell comprising at least one genetic modification at the rghR locus comprises a modified rghR2 gene. In other embodiments, the modified B. licheniformis cell comprising at least one genetic modification at the rghR locus comprises a modified rghR1 gene and a modified rghR2 gene. In other embodiments, the modified B. licheniformis cell comprising at least one genetic modification at the rghR locus comprises a modified rghR1 gene, a modified rghR2 gene, a modified yvzC gene, and a modified bli3644 gene. In certain other embodiments, the modified B. licheniformis cell comprises a deleted rghR locus. In certain other embodiments, the modified cells produce a reduced amount of a red pigment (compared to the parent cell when cultured under the same conditions). In yet other embodiments, the B. licheniformis cells comprise one or more expression cassettes encoding a protein of interest. In certain other embodiments, the one or more expression cassettes encode an amylase protein.

[0012] In other embodiments, the disclosure relates to modified B. licheniformis cells derived from a parent B. licheniformis cell containing a native rghR2 gene, the modified cell comprising at least one genetic modification that mutates, disrupts, partially deletes, or completely deletes the rghR2 gene, the modified cell producing a reduced amount of red pigment (compared to the parent cell when cultured under the same conditions). In certain embodiments, the cell comprises one or more expression cassettes encoding a protein of interest. In certain embodiments, the one or more expression cassettes encode an amylase protein. In certain other embodiments, the modified cell produces an increased amount of the protein of interest (compared to the parent cell when cultured under the same conditions).

[0013] Accordingly, certain other embodiments of the present disclosure relate to a method for producing increased amounts of a protein of interest in an engineered B. licheniformis cell, comprising the steps of: (a) obtaining a B. licheniformis cell and genetically modifying at least one gene in the rghR locus selected from the group consisting of: (i) the rghR1 gene, (ii) the rghR2 gene, (iii) the yvzC gene, and (iv) the Bli3644 gene, or a combination thereof; and b) fermenting the engineered cell of step (a) under conditions suitable for production of the protein of interest, wherein the engineered cell produces increased amounts of the protein of interest (compared to the parental cell when cultured under the same conditions).

[0014] In certain embodiments of the method, the modified rghR1 gene mutates, disrupts, partially deletes, or completely deletes the encoded RghR1 protein, and / or the modified rghR1 gene comprises a genetic modification that mutates, disrupts, partially deletes, or completely deletes the 5'-UTR and / or 3'-UTR sequences of the rghR1 gene, and the modified rghR1 gene does not express the encoded RghR1 protein.

[0015] In other embodiments, the modified rghR2 gene mutates, disrupts, partially deletes, or completely deletes the encoded RghR2 protein, and / or the modified rghR2 gene comprises a genetic modification that mutates, disrupts, partially deletes, or completely deletes the 5'-UTR and / or 3'-UTR sequences of the rghR2 gene, and the modified rghR2 gene does not express the encoded RghR2 protein.

[0016] In another embodiment, the modified yvzC gene mutates, disrupts, partially deletes, or completely deletes the encoded YvzC protein, and / or the modified yvzC gene comprises a genetic modification that mutates, disrupts, partially deletes, or completely deletes the 5'-UTR and / or 3'-UTR sequences of the yvzC gene, and the modified yvzC gene does not express the encoded YvzC protein.

[0017] In certain other embodiments of the method, the modified Bli3644 gene mutates, disrupts, partially deletes, or completely deletes the encoded Bli3644 protein, and / or the modified Bli3644 gene comprises a genetic modification that mutates, disrupts, partially deletes, or completely deletes the 5'-UTR sequence and / or the 3'-UTR of the Bli3644 gene, and the modified Bli3644 gene does not express the encoded Bli3644 protein.

[0018] In another embodiment of the method, the cells comprise one or more expression cassettes encoding a protein of interest. In certain other embodiments, the one or more expression cassettes encode an amylase protein. In another embodiment of the method, the modified B. licheniformis cells produce reduced amounts of red pigment.

[0019] In other embodiments, the disclosure relates to a method for producing a protein of interest in an engineered B. licheniformis cell, the engineered cell producing a reduced amount of red pigment during fermentation, comprising: (a) obtaining a B. licheniformis cell and genetically modifying an rghR2 gene therein; and (b) fermenting the engineered cell under suitable conditions to produce the protein of interest, the engineered cell producing a reduced amount of red pigment (compared to the parent cell when cultured under the same conditions). In certain other embodiments, the engineered rghR2 gene comprises a genetic modification that mutates, disrupts, partially deletes, or completely deletes the encoded RghR2 protein. In other embodiments, the cell comprises one or more expression cassettes encoding a protein of interest. In certain other embodiments, the one or more expression cassettes encode an amylase protein. In other embodiments, the engineered cell produces an increased amount of the protein of interest (compared to the parent cell when cultured under the same conditions). [Brief description of the drawings]

[0020] [Figure 1]Schematic diagram of the B. licheniformis chromosomal "rghR locus." The wild-type rghR locus (FIG. 1A) contains the rghR1 gene (white arrow), the rghR2 gene (black arrow), the yvzC gene (gray arrow), and the Bli3644 gene (striped arrow). As further described in the Examples section below, FIG. 1B shows a modified rghR locus that includes the rghR2stop allele (white arrow showing three asterisks indicating the stop codon), the native rghR1 gene (black arrow), the native yvzC gene (gray arrow) and the native Bli3644 gene (striped arrow); FIG. 1C shows a modified rghR locus that includes the deleted rghR1 (ΔrghR1) allele, the native rghR2 gene (white arrow), the native yvzC gene (gray arrow) and the native Bli3644 gene (striped arrow); FIG. 1D shows a modified rghR locus that includes the deleted rghR2 (ΔrghR2) allele. 1A shows the rghR locus containing the native rghR1 gene (black arrow), the native yvzC gene (gray arrow) and the native Bli3644 gene (striped arrow); FIG. 1E shows a modified rghR locus containing a deleted rghR2 (ΔrghR2) allele, a deleted rghR1 (ΔrghR1) allele, the native yvzC gene (gray arrow) and the native Bli3644 gene (striped arrow); and FIG. 1F shows a modified (empty) rghR locus containing deletions of rghR2, rghR1, yvzC and Bli3644 alleles (ΔrghR2 / ΔrghR1 / ΔyvzC / Δ3644).

[0021] A brief description of biological sequences SEQ ID NO:1 is the amino acid sequence of the S. pyogenes Cas9 protein.

[0022] SEQ ID NO:2 is a nucleic acid encoding the Cas9 protein of SEQ ID NO:1, the nucleic acid sequence of which has been codon-optimized for expression in a Bacillus host strain.

[0023] SEQ ID NO:3 is the amino acid N-terminal nuclear localization sequence (NLS).

[0024] SEQ ID NO:4 is the amino acid C-terminal nuclear localization sequence (NLS).

[0025] SEQ ID NO:5 is the deca-histidine (His) tag amino acid sequence.

[0026] SEQ ID NO:6 is the B. subtilis aprE promoter nucleic acid sequence.

[0027] SEQ ID NO:7 is a synthetic terminator nucleic acid sequence.

[0028] SEQ ID NO:8 is the forward primer nucleic acid sequence.

[0029] SEQ ID NO:9 is the reverse primer nucleic acid sequence.

[0030] SEQ ID NO:10 is the pKB320 backbone nucleic acid sequence.

[0031] SEQ ID NO:11 is the nucleic acid sequence of plasmid pKB320.

[0032] SEQ ID NO:12 is the forward primer nucleic acid sequence.

[0033] SEQ ID NO:13 is the reverse primer nucleic acid sequence.

[0034] SEQ ID NO:14 is the reverse sequencing primer.

[0035] SEQ ID NO:15 is the reverse sequencing primer.

[0036] SEQ ID NO:16 is the forward sequencing primer.

[0037] SEQ ID NO:17 is the forward sequencing primer.

[0038] SEQ ID NO:18 is the forward sequencing primer.

[0039] SEQ ID NO:19 is the forward sequencing primer.

[0040] SEQ ID NO:20 is the forward sequencing primer.

[0041] SEQ ID NO:21 is the forward sequencing primer.

[0042] SEQ ID NO:22 is the forward sequencing primer.

[0043] SEQ ID NO:23 is the reverse sequencing primer.

[0044] SEQ ID NO:24 is the forward sequencing primer.

[0045] SEQ ID NO:25 is the nucleic acid sequence of plasmid pRF694.

[0046] SEQ ID NO:26 is the nucleic acid sequence of plasmid pRF801.

[0047] SEQ ID NO:27 is the nucleic acid sequence of plasmid pRF806.

[0048] SEQ ID NO:28 is the B. licheniformis target site 1 (TS1) nucleic acid sequence.

[0049] SEQ ID NO:29 is the B. licheniformis target site 2 (TS2) nucleic acid sequence.

[0050] SEQ ID NO:30 is the B. licheniformis serA open reading frame nucleic acid sequence.

[0051] SEQ ID NO:31 is the B. licheniformis target site 1 (TS1) PAM nucleic acid sequence.

[0052] SEQ ID NO:32 is a nucleic acid sequence encoding the B. licheniformis variable targeting (VT) site 1.

[0053] SEQ ID NO:33 is a nucleic acid sequence encoding the Cas9 endonuclease recognition (CER) domain.

[0054] SEQ ID NO:34 is a guide RNA (gRNA) nucleic acid sequence targeting site 1.

[0055] SEQ ID NO:35 is the spac promoter nucleic acid sequence.

[0056] SEQ ID NO:36 is the t0 terminator nucleic acid sequence.

[0057] SEQ ID NO:37 is the B. licheniformis serA1 homology arm 1 nucleic acid sequence.

[0058] SEQ ID NO:38 is the synthetic serA1 homology arm 1 forward primer sequence.

[0059] SEQ ID NO:39 is the synthetic serA1 homology arm 1 reverse primer sequence.

[0060] SEQ ID NO:40 is the B. licheniformis serA1 homology arm 2 nucleic acid sequence.

[0061] SEQ ID NO:41 is the synthetic serA1 homology arm 2 forward primer sequence.

[0062] SEQ ID NO:42 is the synthetic serA1 homology arm 2 reverse primer sequence.

[0063] SEQ ID NO:43 is an expression cassette encoding the target site 1 (TS1) gRNA.

[0064] SEQ ID NO:44 is a synthetic serA1 deletion editing template.

[0065] SEQ ID NO:45 is the B. licheniformis rghR1 open reading frame nucleic acid sequence.

[0066] SEQ ID NO:46 is the targeting site 2 (TS2) PAM nucleic acid sequence.

[0067] SEQ ID NO:47 is a nucleic acid sequence encoding variable targeting (VT) site 2.

[0068] SEQ ID NO:48 is a gRNA nucleic acid sequence targeting site 2.

[0069] SEQ ID NO:49 is the B. licheniformis homology arm 1 nucleic acid sequence.

[0070] SEQ ID NO:50 is the synthetic rghR1 homology arm 1 forward sequence.

[0071] SEQ ID NO:51 is the synthetic rghR1 homology arm 1 reverse sequence.

[0072] SEQ ID NO:52 is the B. licheniformis rghR1 homology arm 2 nucleic acid sequence.

[0073] SEQ ID NO:53 is the synthetic rghR1 homology arm 2 forward sequence.

[0074] SEQ ID NO:54 is the synthetic rghR1 homology arm 2 reverse sequence.

[0075] SEQ ID NO:55 is a synthetic nucleic acid expression cassette encoding the target site 2 (TS2) gRNA.

[0076] SEQ ID NO:56 is a synthetic rghR1 deletion mutant template sequence.

[0077] SEQ ID NO: 57 is the amino acid sequence of the Cas9(Y155H) mutant protein.

[0078] SEQ ID NO: 58 is the Cas9(Y155H) forward primer sequence.

[0079] SEQ ID NO:59 is the Cas9(Y155H) reverse primer sequence.

[0080] SEQ ID NO:60 is the nucleic acid sequence of plasmid pRF827.

[0081] SEQ ID NO:61 is an expression cassette encoding a mutated Cas9(Y155H) protein.

[0082] SEQ ID NO:62 is the nucleic acid sequence of plasmid pRF856.

[0083] SEQ ID NO: 63 is the synthetic Cas9(Y155H) fragment nucleic acid sequence.

[0084] SEQ ID NO: 64 is the Cas9(Y155H) fragment forward primer sequence.

[0085] SEQ ID NO: 65 is the Cas9(Y155H) fragment reverse primer sequence.

[0086] SEQ ID NO:66 is the nucleic acid sequence of plasmid pRF694.

[0087] SEQ ID NO:67 is the pRF694 fragment nucleic acid sequence.

[0088] SEQ ID NO:68 is the pRF694 fragment forward primer sequence.

[0089] SEQ ID NO:69 is the pRF694 reverse primer sequence.

[0090] SEQ ID NO:70 is the nucleic acid sequence of plasmid pRF869.

[0091] SEQ ID NO:71 is the B. licheniformis rghR2 open reading frame nucleic acid sequence.

[0092] SEQ ID NO: 72 is the synthetic rghR2 stop Fragment nucleic acid sequences.

[0093] SEQ ID NO: 73 is the synthetic rghR2 stop This is an editing template sequence.

[0094] SEQ ID NO:74 is the rghR2 gRNA expression cassette.

[0095] SEQ ID NO:75 is the synthetic fragment forward primer.

[0096] SEQ ID NO:76 is the synthetic fragment reverse primer.

[0097] SEQ ID NO:77 is the nucleic acid sequence of the pRF862 backbone.

[0098] SEQ ID NO:78 is the pRF862 backbone forward primer.

[0099] SEQ ID NO:79 is the pRF862 backbone reverse primer.

[0100] SEQ ID NO:80 is the nucleic acid sequence of plasmid pRF874.

[0101] SEQ ID NO:81 is the pRF874 target site and PAM nucleic acid sequence.

[0102] SEQ ID NO:82 is the pRF874 editing template.

[0103] SEQ ID NO:83 is the nucleic acid sequence of plasmid pRF879.

[0104] SEQ ID NO:84 is the pRF879 target site and PAM nucleic acid sequence.

[0105] SEQ ID NO:85 is the pRF879 editing template.

[0106] SEQ ID NO:86 is the nucleic acid sequence of plasmid pRF899.

[0107] SEQ ID NO:87 is the pRF899 and pRF901 target site and PAM nucleic acid sequence.

[0108] SEQ ID NO:88 is the pRF899 editing template.

[0109] SEQ ID NO:89 is the nucleic acid sequence of plasmid pRF901.

[0110] SEQ ID NO:90 is the pRF901 editing template.

[0111] SEQ ID NO:91 is the wild-type rghR2 locus nucleic acid sequence.

[0112] SEQ ID NO:92 is the LysA open reading frame nucleic acid sequence.

[0113] SEQ ID NO:93 is the serA_α-amylase expression cassette.

[0114] SEQ ID NO:94 is a synthetic p3 promoter nucleic acid sequence.

[0115] SEQ ID NO:95 is the aprE 5'-untranslated region (UTR) nucleic acid sequence.

[0116] SEQ ID NO:96 is a nucleic acid sequence encoding the amyL signal sequence.

[0117] SEQ ID NO:97 is a nucleic acid sequence encoding an alpha-amylase protein.

[0118] SEQ ID NO:98 is a nucleic acid sequence encoding the amyL terminator sequence.

[0119] SEQ ID NO:99 is the synthetic amyL_α-amylase expression cassette.

[0120] SEQ ID NO:100 is the B. licheniformis amyL promoter sequence.

[0121] SEQ ID NO:101 is the pB1.comK nucleic acid sequence.

[0122] SEQ ID NO:102 is a nucleic acid sequence encoding the spectinomycin marker.

[0123] SEQ ID NO:103 is the B. licheniformis xylR open reading frame.

[0124] SEQ ID NO:104 is the B. licheniformis xylA promoter sequence.

[0125] SEQ ID NO:105 is the nucleic acid sequence encoding the ComK protein.

[0126] SEQ ID NO: 106 is the forward primer sequence.

[0127] SEQ ID NO: 107 is the reverse primer sequence.

[0128] SEQ ID NO:108 is the B. licheniformis rghR2 targeting region nucleic acid sequence.

[0129] SEQ ID NO: 109 is the synthetic rghR2 stop It is a nucleic acid sequence.

[0130] SEQ ID NO:110 is the forward primer sequence.

[0131] SEQ ID NO:111 is the forward primer sequence.

[0132] SEQ ID NO:112 is the reverse primer sequence.

[0133] SEQ ID NO:113 is the B. licheniformis native rghR1 sequence.

[0134] SEQ ID NO:114 is the rghR1 deletion PCR product.

[0135] SEQ ID NO: 115 is the forward primer sequence.

[0136] SEQ ID NO: 116 is the reverse primer sequence.

[0137] SEQ ID NO:117 is the B. licheniformis native rghR2 PCR product.

[0138] SEQ ID NO:118 is the rghR2 deletion PCR product.

[0139] SEQ ID NO: 119 is the forward primer sequence.

[0140] SEQ ID NO: 120 is the reverse primer sequence.

[0141] SEQ ID NO:121 is the B. licheniformis native rghR1 rghR2 PCR product.

[0142] SEQ ID NO:122 is the rghR1 rghR2 deletion PCR product.

[0143] SEQ ID NO: 123 is the forward primer sequence.

[0144] SEQ ID NO: 124 is the reverse primer sequence.

[0145] SEQ ID NO:125 is the B. licheniformis native locus PCR product.

[0146] SEQ ID NO:126 is the synthetic locus deletion PCR product.

[0147] SEQ ID NO:127 is the B. licheniformis strain LDN143 rghR2 locus nucleic acid sequence.

[0148] SEQ ID NO:128 is the B. licheniformis strain BF314 rghR2 locus nucleic acid sequence.

[0149] SEQ ID NO: 129 is the B. licheniformis strain BF324 rghR2 locus nucleic acid sequence.

[0150] SEQ ID NO: 130 is the B. licheniformis strain BF377 rghR2 locus nucleic acid sequence.

[0151] SEQ ID NO:131 is the B. licheniformis strain BF389 rghR2 locus nucleic acid sequence.

[0152] SEQ ID NO:132 is the B. licheniformis strain BF391 rghR2 locus nucleic acid sequence. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0153] The present disclosure generally relates to compositions and methods for constructing and obtaining Bacillus licheniformis cells (strains) with an increased protein production phenotype. Accordingly, certain other embodiments relate to modified B. licheniformis derived from a parent B. licheniformis cell. In certain other embodiments, the modified B. licheniformis cell comprises a modified rghR locus, where the parent cell from which it was derived comprises a modified rghR locus that comprises a wild-type rghR locus. In certain embodiments, the modified B. licheniformis cell with the modified rghR locus comprises an increased protein production phenotype. In certain other embodiments, the modified B. licheniformis cell with the modified rghR locus produces a reduced amount of red pigment. In certain other embodiments, the modified B. licheniformis cells comprise an increased protein production phenotype and produce reduced amounts of a red pigment.

[0154] I. Definition In view of the disclosed modified Bacillus sp. cells and methods thereof described herein, the following terms and phrases are defined. Terms not defined herein should be given their commonly used meaning in the art.

[0155] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the compositions and methods of the present invention belong. Although any methods and materials similar or equivalent to those described herein can also be used to carry out or test the compositions and methods of the present invention, exemplary methods and materials are described below. All publications and patents cited herein are incorporated herein by reference in their entirety.

[0156] It is further noted that the claims may be drafted to exclude optional elements, and thus this statement is intended to serve as a prelude to the use of exclusive terminology such as "solely," "only," "excluding," "not including," or the use of any "negative" limitation or qualification in connection with the recitation of claim elements.

[0157] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has distinct components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the compositions and methods described herein. Any described method may be carried out in the order of events recited or in any other order which is logically possible.

[0158] As used herein, a "host cell" refers to a cell that has the ability to act as a host or expression vehicle for a newly introduced DNA sequence. Thus, in certain embodiments of the present disclosure, the host cell is, for example, a Bacillus sp. cell or an E. coli cell.

[0159] As used herein, an "modified cell" refers to a recombinant (host) cell that contains at least one genetic modification that is not present in the "parent" host cell from which the modified cell is derived.

[0160] For example, in certain embodiments, a "parent" cell is altered (eg, by one or more genetic modifications introduced into the parent cell) to generate its "modified" (daughter) cells.

[0161] In certain embodiments, a parent cell may be referred to as a "control cell," particularly when compared to or in relation to an "modified" Bacillus sp. (daughter) cell. As used herein, when expression and / or production of a protein of interest (POI) in an "unmodified" (parent) cell (e.g., a control cell) is compared to expression and / or production of the same POI in an "modified" (daughter) cell, it will be understood that the "modified" and "unmodified" cells are grown / cultured / fermented under identical conditions (e.g., identical conditions of medium, temperature, pH, etc.).

[0162] As used herein, "Bacillus" or "Bacillus species" refers to "Bacillus sp." cells, as known to those of skill in the art, include all species within the genus "Bacillus," such as, but not limited to, B. subtilis, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. clausii, B. halodurans, B. megaterium, B. coagulans, B. circulans, B. lautus, and B. thuringiensis. It is recognized that the genus Bacillus continues to undergo taxonomic reorganization, and thus the genus is intended to include, but is not limited to, reclassified species, such as organisms such as "B. stearothermophilus," which is now designated "Geobacillus stearothermophilus."

[0163] As used herein, the terms "wild-type" and "native" are used interchangeably and refer to a gene, protein, protein mix, cell or strain found in nature.

[0164] As used herein, a "native B. licheniformis rghR2 gene" includes a nucleotide sequence encoding a "native RghR2 protein," and a "mutated-18-BP B. licheniformis rghR2 gene" refers to a "mutated RghR2 protein" (RghR2) described in WO 2018 / 156705, which is incorporated by reference in its entirety. dup For example, the mutant-18-BP rghR2 gene (hereinafter, "rghR2 dup ") was a mutant RghR2 protein (hereafter referred to as "RghR2 dup ") and its mutant RghR2 dup contains six amino acid residue duplications / repeats (i.e., residues "AAASIR" are duplicated).

[0165] As used herein, a "native rghR1 gene" encodes the native RghR1 protein, a "native rghR2 gene" encodes the native RghR2 protein, a "native yvzC gene" encodes the native YvzC protein, and a "native Bli3644 gene" encodes the native Bli3644 protein.

[0166] As used herein, the "native B. licheniformis (chromosomal) rghR locus" (hereinafter "native rghR locus") comprises the "native rghR1 gene", the "native rghR2 gene", the "native yvzC gene" and the "native Bli3644 gene", as diagrammed in FIG. 1A.

[0167] As used herein, the parental B. licheniformis cell, designated "LDN143," contains a native rghR locus.

[0168] As used herein, a "modified B. licheniformis (chromosomal) rghR locus" (hereinafter, "modified rghR locus") comprises at least one genetic modification selected from the genes (or open reading frames thereof) rghR1, rghR2, yvzC, and / or Bli3644, as compared to the native rghR locus. In certain embodiments, a modified B. licheniformis cell comprising a modified rghR locus is derived from a parent B. licheniformis cell comprising a native rghR locus.

[0169] As used herein, the modified B. licheniformis (daughter) cells, designated "BF314," contain the native rghR1 gene, the modified rghR2 gene ("rghR"), and the modified rghR3 gene ("rghR"), as shown diagrammatically in FIG. STOP "; contains three premature stop codons), a modified rghR locus containing the native yvzC gene and the native Bli3644 gene.

[0170] As used herein, the modified B. licheniformis (daughter) cell, designated "BF324," contains a modified rghR locus that contains a deleted rghR1 gene (ΔrghR1), a native rghR2 gene, a native yvzC gene, and a native Bli3644 gene, as diagrammed in FIG. 1C.

[0171] As used herein, the modified B. licheniformis (daughter) cell, designated "BF377," contains a modified rghR locus that contains a native rghR1 gene, a deleted rghR2 gene (ΔrghR2), a native yvzC gene, and a native Bli3644 gene, as diagrammed in FIG. 1D.

[0172] As used herein, the modified B. licheniformis (daughter) cell, designated "BF389," contains a modified rghR locus that contains a deleted rghR1 gene (ΔrghR1), a deleted rghR2 gene (ΔrghR2), a native yvzC gene, and a native Bli3644 gene, as shown diagrammatically in FIG. 1E.

[0173] As used herein, the modified B. licheniformis (daughter) cell, designated "BF391," contains a modified (empty) rghR locus that contains a deleted rghR1 gene (ΔrghR1), a deleted rghR2 gene (ΔrghR2), a deleted yvzC gene (ΔyvzC), and a deleted Bli3644 gene (ΔBli3644), as shown diagrammatically in FIG. 1F.

[0174] As used herein, the term "equivalent position" refers to the amino acid residue position after alignment with a particular polypeptide sequence.

[0175] The terms "modification" and "genetic modification" are used interchangeably and include: (a) the introduction, substitution, or removal of one or more nucleotides in a gene (or its ORF), or the introduction, substitution, or removal of one or more nucleotides in a regulatory element required for the transcription or translation of a gene or its ORF, (b) gene disruption, (c) gene conversion, (d) gene deletion, (e) gene downregulation, (f) directed mutagenesis, and / or (g) random mutagenesis of any one or more genes disclosed herein. For example, genetic modification as used herein includes, but is not limited to, modification of one or more genes selected from the group consisting of rghR1, rghR2, yvzC, BLi3644, etc.

[0176] As used herein, "gene disruption", "gene disruption", "gene inactivation" and "gene inactivation" are used interchangeably and refer broadly to any genetic modification that substantially prevents a host cell from producing a functional gene product (e.g., a protein). Exemplary gene disruption methods include complete or partial loss of any portion of a gene, including a polypeptide coding sequence, promoter, enhancer, or other regulatory element, or mutagenesis of the same, where mutagenesis includes substitutions, insertions, deletions, inversions, and any combinations and variations thereof that disrupt / inactivate the target gene and substantially reduce or prevent production of a functional gene product (i.e., a protein).

[0177] The compound term "express / produce" as used herein, for example in the phrase "the modified (host) cell expresses / produces increased amounts of a protein of interest compared to the parent (host) cell", is intended to include any process involved in the expression and production of a protein of interest in a host cell of the present disclosure.

[0178] Thus, as used herein, "increasing" protein production or "increased" protein production refers to an increased amount of protein (e.g., endogenous and / or heterologous POI) produced. The protein may be produced inside the host cell or secreted (or transported) into the culture medium. In certain embodiments, the protein of interest is produced (secreted) into the culture medium. Increased protein production may be detected, for example, as a higher maximum level of protein or enzyme activity (e.g., protease activity, amylase activity, cellulase activity, hemicellulase activity, etc.) or as total extracellular protein produced, as compared to the parent host cell.

[0179] As used herein, "nucleic acid" refers to DNA, cDNA and RNA of genomic or synthetic origin, whether representing a nucleotide or polynucleotide sequence, as well as fragments or portions thereof, and whether representing the sense or antisense strand, and whether double-stranded or single-stranded. It will be understood that, as a result of the degeneracy of the genetic code, many nucleotide sequences can code for a given protein.

[0180] The polynucleotides (or nucleic acid molecules) described herein are understood to include "genes," "vectors," and "plasmids."

[0181] Thus, the term "gene" refers to a polynucleotide that codes for a particular sequence of amino acids, including all or part of a coding sequence for a protein, and may include regulatory (non-transcribed) DNA sequences, such as promoter sequences, that determine the conditions under which the gene is expressed. The transcribed region of a gene may include introns, untranslated regions (UTRs), including 5'-untranslated regions (UTRs) and 3'-UTRs, as well as the coding sequence.

[0182] As used herein, the term "coding sequence" refers to a nucleotide sequence, which directly specifies the amino acid sequence of its protein product. The boundaries of a coding sequence are generally determined by an open reading frame (hereinafter "ORF"), which usually begins with the ATG start codon. Coding sequences typically include DNA, cDNA, and recombinant nucleotide sequences.

[0183] The term "promoter" as used herein refers to a nucleic acid sequence capable of controlling the expression of a coding sequence or functional RNA. Generally, the coding sequence is located 3' (downstream) of the promoter sequence. Promoters may be derived entirely from a native gene, or may be composed of different elements derived from different naturally occurring promoters, or may even comprise synthetic nucleic acid segments. Those skilled in the art understand that different promoters may direct the expression of genes in different cell types, or at different developmental stages, or in response to different environmental or physiological conditions. The promoters that most often cause the expression of genes in most cell types are generally referred to as "constitutive promoters". Furthermore, it is recognized that DNA fragments of different lengths may have the same promoter activity, since in most cases the exact boundaries of regulatory sequences are not completely clear.

[0184] As used herein, the term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment such that the function of one is affected by the other. For example, a promoter is operably linked to a coding sequence (e.g., an ORF) if it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). A coding sequence can be operably linked to a regulatory sequence in a sense or antisense orientation.

[0185] A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA encoding a secretory leader (i.e., signal peptide) is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. Enhancers, however, need not be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

[0186] As used herein, "a functional promoter sequence (or open reading frame thereof) controlling expression of a gene of interest linked to a gene of a protein coding sequence of interest" refers to a promoter sequence that controls transcription and translation of the coding sequence in Bacillus. For example, in certain embodiments, the present disclosure is directed to a polynucleotide comprising a 5' promoter (or a 5' promoter region or a tandem 5' promoter, etc.), the promoter region being operably linked to a nucleic acid sequence encoding a protein of interest. Thus, in certain embodiments, the functional promoter sequence controls expression of a gene encoding a protein disclosed herein. In other embodiments, the functional promoter sequence controls expression of a heterologous gene (or endogenous gene) encoding a protein of interest in a Bacillus cell, more particularly in a B. licheniformis host cell.

[0187] As defined herein, a "suitable regulatory sequence" refers to a nucleotide sequence located upstream (5' non-coding sequences), within or downstream (3' non-coding sequences) of a coding sequence that influences the transcription, RNA processing or stability or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, RNA processing sites, effector binding sites and stem-loop structures.

[0188] As defined herein, the term "introducing" as used in phrases such as "introducing into a bacterial cell" or "introducing at least one polynucleotide open reading frame (ORF), or gene thereof, or vector thereof, into a B. licheniformis cell" includes methods known in the art for introducing polynucleotides into a cell, including, but not limited to, protoplast fusion, natural or artificial transformation (e.g., calcium chloride, electroporation), transduction, transfection, conjugation, and the like (see, e.g., Ferrari et al., 1989).

[0189] As used herein, "transformed" or "transformation" refers to a cell being transformed by the use of recombinant DNA technology. Transformation typically occurs by inserting one or more nucleotide sequences (e.g., a polynucleotide, ORF, or gene) into a cell. The inserted nucleotide sequence may be a heterologous nucleotide sequence (i.e., a sequence that does not naturally occur in the cell being transformed). For example, in certain embodiments of the present disclosure, a parent B. licheniformis cell is modified (e.g., transformed) by introducing into the parent cell a polynucleotide construct that includes a promoter operably linked to a nucleic acid sequence encoding a protein of interest, thereby resulting in a modified B. licheniformis (daughter) host cell derived from the parent cell.

[0190] As used herein, "transformation" refers to the introduction of foreign DNA into a host cell such that the DNA is maintained as a chromosomal integrant or a self-replicating extrachromosomal vector. As used herein, "transforming DNA," "transforming sequence," and "DNA construct" refer to DNA used to introduce a sequence into a host cell or organism. The transforming DNA is the DNA used to introduce a sequence into a host cell or organism. This DNA can be generated in vitro by PCR or any other suitable technique. In some embodiments, the transforming DNA includes the incoming sequence, while in other embodiments, the transforming DNA further includes the incoming sequence flanked by homology boxes. In yet other embodiments, the transforming DNA includes other non-homologous sequences (i.e., stuffer sequences or flanking sequences) added to the ends. The ends can be closed such that the transforming DNA forms a closed circle, such as, for example, by insertion into a vector.

[0191] As used herein, the term "introduced" in the context of introducing a nucleic acid sequence into a cell refers to any method suitable for transferring a nucleic acid sequence into a cell. Such methods for introduction include, but are not limited to, protoplast fusion, transfection, transformation, electroporation, conjugation, and transduction (see, e.g., Ferrari et al., 1989).

[0192] As used herein, "incoming sequence" refers to a DNA sequence that is introduced into the Bacillus chromosome. In some embodiments, the incoming sequence is part of a DNA construct. In other embodiments, the incoming sequence encodes one or more proteins of interest. In some embodiments, the incoming sequence comprises a sequence that may or may not already be present in the genome of the cell to be transformed (i.e., it may be a homologous or non-homologous sequence). In some embodiments, the incoming sequence encodes one or more proteins of interest, genes and / or mutant or modified genes. In alternative embodiments, the incoming sequence encodes a functional wild-type gene or operon, a functional mutant gene or operon, or a non-functional gene or operon. In some embodiments, a non-functional sequence may be inserted into a gene to disrupt the function of the gene. In another embodiment, the incoming sequence comprises a selection marker. In yet another embodiment, the incoming sequence comprises two homology boxes.

[0193] As used herein, a "homology box" refers to a nucleic acid sequence that is homologous to a sequence in the Bacillus chromosome. More specifically, a homology box is an upstream or downstream region that has about 80-100% sequence identity, about 90-100% sequence identity, or about 95-100% sequence identity with the gene or some immediately adjacent coding region of the gene to be deleted, disrupted, inactivated, downregulated, etc., according to the present invention. These sequences direct where in the Bacillus chromosome the DNA construct is integrated and direct what part of the Bacillus chromosome is replaced by the incoming sequence. While not intending to limit the disclosure, a homology box can include from about 1 base pair (bp) to 200 kilobases (kb). Preferably, the homology box comprises about 1 bp to 10.0 kb; 1 bp to 5.0 kb; 1 bp to 2.5 kb; 1 bp to 1.0 kb, and 0.25 kb to 2.5 kb. The homology box may also comprise about 10.0 kb, 5.0 kb, 2.5 kb, 2.0 kb, 1.5 kb, 1.0 kb, 0.5 kb, 0.25 kb, and 0.1 kb. In some embodiments, the 5' and 3' ends of the selectable marker are flanked by homology boxes, where the homology box comprises nucleic acid sequences that are immediately adjacent to the coding region of a gene.

[0194] As used herein, the term "nucleotide sequence encoding a selectable marker" refers to a nucleotide sequence that is expressible in a host cell and in which expression of the selectable marker confers on a cell containing the expressed gene the ability to grow in the presence of a corresponding selection agent or in the absence of an essential nutrient.

[0195] As used herein, the terms "selectable marker" and "selection marker" refer to a nucleic acid (e.g., a gene) that can be expressed in a host cell to facilitate the selection of those hosts that contain a vector. Examples of such selectable markers include, but are not limited to, antimicrobial agents. Thus, the term "selectable marker" refers to a gene that provides an indication that a host cell has taken up an incoming DNA of interest or that some other reaction has occurred. Typically, a selectable marker is a gene that confers an antimicrobial resistance or a metabolic advantage to a host cell that allows cells that contain foreign DNA to be distinguished from cells that have not received the exogenous sequence during transformation.

[0196] An "present selectable marker" is a marker that is located on the chromosome of the microorganism being transformed. The present selectable marker encodes a different gene than the selectable marker on the transforming DNA construct. Selectable markers are well known to those skilled in the art. As indicated above, markers include antimicrobial resistance markers (e.g., amplicons ... R , phleo R , spec R , kan R ,ery R , tet R , cmp R and neo R(See, e.g., Guerot-Fleury, 1995; Palmeros et al., 2000; and Trieu-Cuot et al., 1983). In some embodiments, the invention provides a chloramphenicol resistance gene (e.g., a gene present on pC194, as well as a resistance gene present in the genome of Bacillus licheniformis). This resistance gene is particularly useful in the present invention and in embodiments involving chromosomal amplification of chromosomally integrated cassettes and integrative plasmids (See, e.g., Albertini and Galizzi, 1985; Stahl and Ferrari, 1984). Other markers useful according to the invention include, but are not limited to, auxotrophic markers such as serine, lysine, tryptophan, and detection markers such as β-galactosidase or fluorescent proteins.

[0197] As defined herein, a host cell "genome," a bacterial (host) cell "genome," or a B. licheniformis (host) cell "genome" includes chromosomal genes and extrachromosomal genes.

[0198] As used herein, the terms "plasmid," "vector," and "cassette" refer to extrachromosomal elements, usually in the form of circular double-stranded DNA molecules, that often carry genes that are not typically involved in the central metabolism of a cell. Such elements may be linear or circular, single-stranded or double-stranded, autonomously replicating sequences of DNA or RNA, genome-integrating sequences, phages, or nucleotide sequences from any source in which multiple nucleotide sequences have been joined or recombined into a unique configuration that allows the introduction of promoter fragments and DNA sequences for selected gene products, along with appropriate 3'-non-translated sequences, into a cell.

[0199] As used herein, a "transformation cassette" refers to a specific vector that contains a gene (or its ORF) and has elements in addition to a foreign gene that facilitate transformation of a particular host cell.

[0200] The term "vector" as used herein refers to any nucleic acid that can replicate (multiply) in a cell and can carry new genes or DNA segments into the cell. Thus, the term refers to a nucleic acid construct designed for transport between various host cells. Vectors include viruses, bacteriophages, proviruses, plasmids, phagemids, transposons, which are "episomes" (i.e., they can replicate autonomously or integrate into the chromosomes of the host organism), as well as artificial chromosomes, such as YACs (yeast artificial chromosomes), BACs (bacterial artificial chromosomes), and PLACs (plant artificial chromosomes).

[0201] "Expression vector" refers to a vector capable of incorporating and expressing heterologous DNA in a cell. Many prokaryotic and eukaryotic expression vectors are commercially available and known to those skilled in the art. The selection of an appropriate expression vector is within the knowledge of one of ordinary skill in the art.

[0202] The terms "expression cassette" and "expression vector" as used herein refer to a nucleic acid construct (i.e., they are vectors or vector elements as described above) that is recombinantly or synthetically produced with a set of specific nucleic acid elements that allow transcription of a specific nucleic acid in a target cell. The recombinant expression cassette can be incorporated into a plasmid, a chromosome, mitochondrial DNA, plastid DNA, a virus, or a nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter. In some embodiments, the DNA construct also includes a set of specific nucleic acid elements that allow transcription of a specific nucleic acid in a target cell. In certain embodiments, the DNA construct of the present disclosure includes a selectable marker and an inactivated chromosomal segment or gene segment or DNA segment as defined herein.

[0203] As used herein, a "targeting vector" is a vector that contains a polynucleotide sequence that is homologous to a region in a host cell chromosome into which the targeting vector is transformed and can drive homologous recombination at that region. For example, a targeting vector is used to introduce a mutation into a host cell chromosome by homologous recombination. In some embodiments, the targeting vector contains other non-homologous sequences (i.e., stuffer sequences or flanking sequences), for example, added to the ends. In some embodiments, the targeting vector contains elements to increase homologous recombination, including, but not limited to, RNA-guided endonucleases, DNA-guided endonucleases, and recombinases. The ends can be closed such that the targeting vector forms a closed circle, for example, by insertion into a vector.

[0204] As used herein, the term "plasmid" refers to a circular, double-stranded (ds) DNA construct that is used as a cloning vector and forms an extrachromosomal, self-replicating genetic element in many bacteria and some eukaryotes. In some embodiments, the plasmid is integrated into the genome of the host cell.

[0205] The term "protein of interest" or "POI" as used herein refers to a polypeptide of interest that is desired to be expressed in a Bacillus sp. host cell, with the POI preferably being expressed at increased levels. Thus, as used herein, a POI can be an enzyme, a substrate binding protein, a surfactant protein, a structural protein, a receptor protein, etc. In certain embodiments, the engineered cells of the present disclosure produce an increased amount of a heterologous POI or an increased amount of an endogenous POI compared to a parent cell. In certain embodiments, the increased amount of POI produced by the engineered cells of the present disclosure is at least a 0.5% increase, at least a 1.0% increase, at least a 5.0% increase, or more than a 5.0% increase compared to a parent cell.

[0206] Similarly, a "gene of interest" or "GOI" as defined herein refers to a nucleic acid sequence (e.g., polynucleotide, gene or ORF) that encodes a POI. A "gene of interest" that encodes a "protein of interest" may be a naturally occurring gene, a mutated gene or a synthetic gene.

[0207] As used herein, the terms "polypeptide" and "protein" are used interchangeably and refer to polymers of any length that contain amino acid residues linked by peptide bonds. Conventional one-letter or three-letter codes for amino acid residues are used herein. Polypeptides may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. The term polypeptide also encompasses amino acid polymers that are modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling moiety. Also included within the scope of this definition are, for example, polypeptides that contain one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art.

[0208] In certain embodiments, the genes of the present disclosure are those encoding enzymes (e.g., acetyl esterase, aminopeptidase, amylase, arabinase, arabinofuranosidase, carbonic anhydrase, carboxypeptidase, catalase, cellulase, chitinase, chymosin, cutinase, deoxyribonuclease, epimerase, esterase, α-galactosidase, β-galactosidase, α-glucanase, glucan lyase, lysase), endo-β-glucanase, glucoamylase, glucose oxidase, α-glucosidase, β-glucosidase, glucuronidase, glycosyl hydrolase, hemicellulase, hexose oxidase, hydrolase, invertase, isomerase, laccase, lipase, lyase, mannosidase, oxidase, oxidoreductase, pectate lyase, pectin acetyl esterase, pectin depolymerase, pectin methyl esterase, pectinolytic enzyme, perhydrolase, polyol oxidase, peroxidase, phenol oxidase, phytase, polygalacturonase, protease, peptidase, rhamno-galacturonase, ribonuclease, transferase, transport protein, transglutaminase, xylanase, hexose oxidase, and combinations thereof.

[0209] As used herein, a "mutant" polypeptide refers to a polypeptide derived from a parent (or reference) polypeptide by one or more amino acid substitutions, additions, or deletions, typically by recombinant DNA techniques. A mutant polypeptide can differ from a parent polypeptide by a small number of amino acid residues and can be defined by the level of primary amino acid sequence homology / identity with the parent (reference) polypeptide.

[0210] Preferably, a variant polypeptide has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or even at least 99% amino acid sequence identity with a parent (reference) polypeptide sequence. As used herein, a "variant" polynucleotide refers to a polynucleotide that encodes a variant polypeptide, which has a particular degree of sequence homology / identity with a parent polynucleotide or hybridizes to a parent polynucleotide (or its complement) under stringent hybridization conditions. Preferably, the variant nucleotide has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or even at least 99% nucleotide sequence identity with the parent (reference) polynucleotide sequence.

[0211] As used herein, "mutation" refers to any change or alteration in a nucleic acid sequence. There are several types of mutations, including point mutations, deletion mutations, silent mutations, frameshift mutations, splicing mutations, etc. Mutations can be made specifically (e.g., by site-directed mutagenesis) or randomly (e.g., by chemicals, repair minus passaging through bacterial strains).

[0212] As used herein, in reference to a polypeptide or sequence thereof, the term "substitution" refers to the replacement (ie, substitution) of one amino acid with another.

[0213] As defined herein, "endogenous gene" refers to a gene that is present in its natural location in the genome of an organism.

[0214] A "heterologous" gene, "non-endogenous" gene or "foreign" gene, as defined herein, refers to a gene (or ORF) that is not normally found in the host organism, but which has been introduced into the host organism by gene transfer. As used herein, the term "foreign" gene includes a native gene (or ORF) inserted into a non-native organism and / or a chimeric gene inserted into a native or non-native organism.

[0215] A "heterologous" nucleic acid construct or "heterologous" nucleic acid sequence, as defined herein, has a portion of sequence that is not native to the cell in which it is expressed.

[0216] As defined herein, a "heterologous control sequence" refers to a gene expression control sequence (e.g., a promoter or enhancer) that does not function in nature to regulate (control) the expression of a gene of interest. Generally, heterologous nucleic acid sequences are not endogenous (natural) to the cell or part of the genome in which they are present, but have been added to the cell by infection, transfection, transformation, microinjection, electroporation, etc. A "heterologous" nucleic acid construct may contain a control sequence / DNA coding (ORF) sequence combination that is the same or different from the control sequence / DNA coding sequence combination found in the native host cell.

[0217] The terms "signal sequence" and "signal peptide" as used herein refer to a sequence of amino acid residues that may be involved in the secretion or direct transport of a mature protein or a precursor form of a protein. A signal sequence is typically located at the N-terminus of a precursor or mature protein sequence. A signal sequence may be endogenous or foreign. A signal sequence is not usually present in a mature protein. A signal sequence is typically cleaved from a protein by a signal peptidase after the protein has been transported.

[0218] The term "derived from" includes the terms "originating from," "obtained from," "available from," and "made from," and generally indicates that one particular material or composition has characteristics that can be found its origin in another material or composition, or that can be described with reference to that other particular material or composition.

[0219] The term "homology" as used herein relates to homologous polynucleotides or homologous polypeptides. When two or more polynucleotides or two or more polypeptides are homologous, this means that the homologous polynucleotides or polypeptides have a "degree of identity" of at least 60%, more preferably at least 70%, even more preferably at least 85%, even more preferably at least 90%, more preferably at least 95%, and most preferably at least 98%. Whether two polynucleotide or polypeptide sequences have a sufficiently high degree of identity to be homologous as defined herein can be conveniently determined by aligning the two sequences using a computer program known in the art, for example, "GAP" provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman and Wunsch, (1970). GAP is used with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3.

[0220] As used herein, the term "percent identity" refers to the level of nucleic acid or amino acid sequence identity between nucleic acid sequences encoding a polypeptide or between the amino acid sequences of a polypeptide when aligned using a sequence alignment program.

[0221] As used herein, the term "specific productivity" refers to the total amount of protein produced per cell per unit time over a given period of time.

[0222] The terms "purified," "isolated," or "enriched," as defined herein, refer to a biomolecule (e.g., a polypeptide or polynucleotide) that has been altered from its native state by separation from some or all of the naturally occurring components with which it is naturally associated. Such isolation or purification can be accomplished by separation techniques known in the art, such as ion exchange chromatography, affinity chromatography, hydrophobic separation, dialysis, protease treatment, ammonium sulfate precipitation or other protein salting out, centrifugation, size exclusion chromatography, filtration, microfiltration, gel electrophoresis, or gradient separation to remove unwanted whole cells, cell debris, impurities, extraneous proteins, or enzymes in the final composition. Purified or isolated biomolecule compositions can then be supplemented with components that confer additional benefits, such as activators, anti-inhibitors, desirable ions, pH adjusting compounds, or other enzymes or chemicals.

[0223] As used herein, the term "ComK polypeptide" is defined as the product of the comK gene, a transcription factor that acts as a final autoregulatory control switch before the development of competence, involved in activating the expression of late competence genes involved in DNA binding and uptake and recombination (Liu and Zuber, 1998, Hamoen et al., 1998).

[0224] As used herein, "homologous genes" refers to a pair of genes from different but usually related species that correspond to each other and are identical or highly similar to each other. The term encompasses genes that have been separated by speciation (i.e., the emergence of new species) (e.g., orthologous genes) and genes that have been separated by genetic duplication (e.g., paralogous genes).

[0225] As used herein, "ortholog" and "orthologous genes" refer to genes in different species that have arisen from a common ancestral gene (i.e., a homologous gene) by speciation. Typically, orthologs retain the same function during the course of evolution. Identification of orthologs is used for reliable prediction of gene function in newly sequenced genomes.

[0226] As used herein, "paralog" and "paralogous genes" refer to genes that are involved in duplication within a genome. Orthologs retain the same function throughout evolution, while paralogs give rise to new functions, although some functions are often related to the original. Examples of paralogous genes include, but are not limited to, genes encoding trypsin, chymotrypsin, elastase, and thrombin, all of which are serine proteinases and occur together in the same species.

[0227] As used herein, "homology" refers to sequence similarity or identity, with identity being preferred, which is determined using standard techniques known in the art (see, e.g., Smith and Waterman, 1981; Needleman and Wunsch, 1970; Pearson and Lipman, 1988; programs such as GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, WI); and Devereux et al., 1984).

[0228] The term "hybridization" as used herein refers to the process by which a nucleic acid strand binds with its complementary strand by base pairing, as known in the art. A nucleic acid sequence is considered to be "selectively hybridizable" to a reference nucleic acid sequence if the two sequences specifically hybridize to each other under medium to high stringency hybridization and wash conditions. Hybridization conditions are determined by the melting temperature (Tm For example, "maximum stringency" is usually based on T m - 5°C (T m 5°C below T m and "intermediate stringency" is approximately 5-10°C below the T m and "low stringency" is T m This occurs when the temperature drops by about 20 to 25 degrees Celsius.

[0229] Functionally, maximum stringency conditions can be used to identify sequences with exact or near exact identity to the hybridization probe, while intermediate or low stringency hybridization can be used to identify or detect polynucleotide sequence homologs. Medium to high stringency hybridization conditions are well known in the art. Examples of high stringency conditions include hybridization at about 42°C in 50% formamide, 5xSSC, 5xDenhardt's solution, 0.5% SDS and 100pg / mL denatured carrier DNA, followed by two washes at room temperature (RT) in 2xSSC and 0.5% SDS, and two additional washes at 42°C in 0.1xSSC and 0.5% SDS. An example of moderately stringent conditions includes overnight incubation at 37° C. in a solution containing 20% ​​formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 mg / mL denatured, fragmented salmon sperm DNA, followed by washing of the filter in 1×SSC at about 37-50° C. One of skill in the art will know how to adjust temperature, ionic strength, etc. as necessary to accommodate factors such as probe length.

[0230] As used herein, "recombinant" includes reference to a cell or vector that has been modified by the introduction of a heterologous nucleic acid sequence, or that is derived from a cell that has been so modified. Thus, for example, a recombinant cell expresses a gene that is not found in the same form within the native (non-recombinant) form of the cell, or expresses a native gene that is otherwise abnormally expressed, under-expressed, or not expressed at all as a result of deliberate human intervention. "Recombinant," "recombining," or producing a "recombinant" nucleic acid is generally the assembly of two or more nucleic acid fragments, which assembly gives rise to a chimeric gene.

[0231] As used herein, "flanking sequence" refers to any sequence that is upstream or downstream of the sequence under consideration (e.g., in gene ABC, gene B is flanked by gene sequences A and C). In certain embodiments, the incoming sequence is flanked on both sides by homology boxes. In other embodiments, the incoming sequence and the homology box comprise a unit that is flanked on both sides by stuffer sequences. In some embodiments, the flanking sequences are present on only one side (3' or 5'), but in preferred embodiments, they are present on both sides of the sequence that they are flanking. The sequence of each homology box is homologous to a sequence in the Bacillus chromosome. These sequences direct where in the Bacillus chromosome the new construct will be integrated and which part of the Bacillus chromosome will be replaced by the incoming sequence. In other embodiments, the 5' and 3' ends of the selectable marker are flanked by polynucleotide sequences that comprise a portion of an inactivated chromosomal segment. In some embodiments, flanking sequences are present on only one side (3' or 5'), while in other embodiments, they are present on both sides of the sequences they are flanking. In some embodiments, the homology boxes directly flank each other or lack intervening sequences (e.g., constructs D through F for genes DEF) such that when the constructs recombine in the genome, gene E will be removed from the genome.

[0232] II. Bacillus licheniformis RGHR locus The Bacillus subtilis yvaN gene has been identified as a repressor of the rapG, rapH, and rapD genes and has been designated "rghR" (i.e., rapG and rapH repressor; Hayashi et al., 2006; Ogura & Fujita, 2007). For example, the B. licheniformis rghR locus encodes two homologs of the B. subtilis RghR / YvaO (transcriptional regulator), designated "RghR1" and "RghR2". Upstream (5') of the B. licheniformis rghR1 gene (see, e.g., Figure 1A) are two additional genes, yvzC(Bli3645) and Bli3644, which encode the transcriptional regulator proteins YvzC and Bli3644, respectively. More particularly, as generally defined above, the native B. licheniformis rghR (chromosomal) locus includes a native rghR1 gene, a native rghR2 gene, a native yvzC gene, and a native Bli3644 gene, as shown in FIG. 1A. For example, WO 2018 / 156705 describes "RghR2 dup The present invention discloses a mutant B. licheniformis strain comprising a mutant rghR2 gene having a nucleotide sequence encoding a mutant RghR2 protein designated "AAASIR" (i.e., comprising six amino acid repeats of "AAASIR"). dup Deletion of an 18-bp duplication from the sequence (i.e., allele rghR2 rest (resulting in a reduction in biomass with a concomitant increase in heterologous protein production).

[0233] As described herein and in the Examples section below, Applicant further designed, constructed, and tested modified B. licheniformis to evaluate the rghR locus and to identify B. licheniformis cells with enhanced protein production (or other beneficial) phenotypes. More specifically, in this example, a parent B. licheniformis cell, designated LDN143, containing the native rghR locus (FIG. 1A) with deletions of the serA and lysA genes and containing two heterologous α-amylase expression cassettes was evaluated against modified B. licheniformis (daughter) cells (i.e., derived from the LDN143 parent) containing the modified rghR locus. Therefore, the modified B. licheniformis (daughter) cells described herein were constructed with a series of modified rghR locus alleles introduced into a parent B. licheniformis cell (LDN143).

[0234] More specifically, the following modified rghR locus: the native rghR1 gene, the modified rghR2 gene (rghR2 STOP ), B. licheniformis cells BF314 containing the native yvzC gene and the native Bli3644 gene (Figure 1B), a deleted rghR1 gene (ΔrghR1), a native rghR2 gene (rghR2 STOP), B. licheniformis cell BF324 containing the native yvzC gene and the native Bli3644 gene (Figure 1C), B. licheniformis cell BF377 containing the native rghR1 gene, the deleted rghR2 gene (ΔrghR2), the native yvzC gene and the native Bli3644 gene (Figure 1D), and B. licheniformis cell BF377 containing the deleted rghR1 gene (ΔrghR1), the deleted rghR2 gene (ΔrghR2), the native yvzC gene and the native Bli3644 gene. The following B. licheniformis (daughter) cells derived from the LDN143 parent were constructed, including B. licheniformis cell BF389 (Figure 1E) and one of B. licheniformis cell BF391 (Figure 1F, empty rghR locus) containing the deleted rghR1 gene (ΔrghR1), the deleted rghR2 gene (ΔrghR2), the deleted yvzC gene (ΔyvzC), and the deleted Bli3644 gene (ΔBli3644).

[0235] Thus, as described in Example 4 below (see, e.g., Table 20), modified B. licheniformis cells with mutations at the rghR locus demonstrated an increased production phenotype that produced about 23-62% more amylase protein than a comparable parent cell (LDN143) that was wild-type for the rghR locus. Certain embodiments of the present disclosure thus relate to such modified Bacillus cells having a modified rghR locus and comprising an increased protein production phenotype. Certain other embodiments relate to methods for constructing and obtaining such compositions and modified Bacillus cells. Certain other embodiments thus relate to expression / production of endogenous and / or heterologous proteins of interest that are modified Bacillus cells of the present disclosure.

[0236] III. BACILLUS LICHENIFORMIS CELLS PRODUCING REDUCED QUANTITIES OF RED PIGMENTS As is generally understood by those skilled in the art, the genus Bacilli is well-known as a host system for the production of native and recombinant proteins. However, certain Bacillus species (e.g., B. subtilis, B. cereus, B. licheniformis, etc.) secrete cyclo-L-leucyl-L-leucyl-derived pulcherrimic acid into the growth medium and chelate iron ions (by a nonenzymatic reaction) to produce an extracellular red pigment known as pulcherrimin (MacDonald, 1965; Uffen and Canale-Parola, 1972). Thus, Bacillus sp. (host) cells that produce pulcherrimin in sufficient quantities to produce a visible red pigment (i.e., during fermentation / culture) will generally require one or more pulcherrimin recovery steps during recovery and / or purification of the protein of interest, or pulcherrimin (red pigment) may be co-purified with the protein of interest.

[0237] For example, a Bacillus sp. with a desired phenotype (e.g., increased protein production, etc.) does not necessarily have the most desirable characteristics (e.g., a red pigment phenotype, etc.) for successful fermentation, recovery and / or purification of a protein of interest produced by the host cell. Accordingly, certain genetic approaches to reduce the production of pulcherrimin in Bacillus cells have been described in the art, such as WO 2004 / 011609, which describes the deletion of the cypX and / or yvmC genes in Bacillus as a means to reduce pulcherrimin production.

[0238] As described herein and in the Examples section below, Applicants have identified a novel means for attenuating the production of a red pigment (pulcherrimin) in Bacillus licheniformis cells. More specifically, as presented and described in Example 5 below, an identified feature of the rghR locus is the transcriptional regulation of the operon responsible for producing the iron-scavenging pigment, pulcherrimic acid. As described in this Example, B. licheniformis cells BF314 (i.e., modified (rghR2 STOP ) gene) and BF377 (i.e., containing the deleted (ΔrghR2) gene) both demonstrate a reduction in the production of red pigment to about 30-50%, whereas several other mutations increased the production of pulcherrimin to about 10-20% (see, e.g., Table 21), indicating that mutations at the rghR locus control the biosynthesis of pulcherrimic acid.

[0239] Thus, certain embodiments of the present disclosure relate to engineered Bacillus cells having an engineered rghR locus that produce reduced amounts of red pigments. Certain other embodiments relate to such compositions and methods for constructing and obtaining engineered Bacillus cells that produce reduced amounts of red pigments. Certain other embodiments relate to the expression / production of endogenous and / or heterologous proteins of interest that are engineered Bacillus cells of the present disclosure.

[0240] IV. Molecular Biology As explained above, certain embodiments of the present disclosure relate to modified B. licheniformis cells derived from a parent B. licheniformis cell that contains a native rghR locus. In certain other embodiments, the modified B. licheniformis cell contains a modified rghR locus. Thus, certain other embodiments relate to compositions and methods for genetically modifying a parent B. licheniformis cell to generate modified B. licheniformis (daughter) cells.

[0241] Certain embodiments of the present disclosure are thus directed to methods for genetically modifying a Bacillus cell, the modification including, but not limited to, (a) introduction, substitution or removal of one or more nucleotides in a gene (or its ORF) or in a regulatory element required for transcription or translation of the gene or its ORF, (b) gene disruption, (c) gene conversion, (d) gene deletion, (e) gene downregulation, (f) site-directed mutagenesis, and / or (g) random mutagenesis. For example, genetic modification as used herein includes, but is not limited to, modification of one or more genes selected from the group consisting of the B. licheniformis rghR1 gene, rghR2 gene, yvzC gene, and BLi3644 gene.

[0242] Thus, in certain embodiments, an altered Bacillus cell of the present disclosure is constructed by reducing or eliminating expression of the genes defined above using methods well known in the art, such as insertion, disruption, substitution or deletion. The portion of the gene to be altered or inactivated can be, for example, the coding region or a regulatory element required for expression of the coding region.

[0243] An example of such a regulatory or control sequence may be a promoter sequence or a functional portion thereof (i.e., a portion sufficient to affect the expression of a nucleic acid sequence). Other control sequences for modification include, but are not limited to, leader sequences, propeptide sequences, signal sequences, transcription terminators, transcription activators, and the like.

[0244] In certain other embodiments, modified Bacillus cells are constructed by gene deletion to eliminate or reduce expression of at least one of the above genes of this disclosure. Gene deletion techniques allow for partial or complete removal of genes, thereby eliminating their expression or expressing a non-functional (or reduced activity) protein product. In such methods, deletion of the gene can be accomplished by homologous recombination using a plasmid that has been constructed to contain adjacent 5' and 3' regions flanking the gene. The adjacent 5' and 3' regions can be introduced into the Bacillus cell on a temperature sensitive plasmid, such as pE194, associated with a second selectable marker at a permissive temperature that allows the plasmid to become established in the cell. The cells are then shifted to a non-permissive temperature to select for cells that have the plasmid integrated into the chromosome at one of the homologous flanking regions. Selection for integration of the plasmid is performed by selection for the second selectable marker. After integration, recombination events at the second homologous flanking region are stimulated by shifting the cells to a permissive temperature for several generations without selection. The cells are plated to obtain single colonies, which are tested for the loss of both selectable markers (see, e.g., Perego, 1993). Thus, one skilled in the art can easily identify nucleotide regions in the coding sequence of a gene and / or in the non-coding sequence of a gene that are suitable for complete or partial deletion (e.g., by reference to the rghR1, rghR2, yvzC, bli3644 (nucleic acid) sequences and their encoded protein sequences).

[0245] In other embodiments, modified Bacillus cells of the present disclosure are constructed by introducing, substituting, or removing one or more nucleotides within genes or regulatory elements required for their transcription or translation. For example, nucleotides may be inserted or removed to introduce a stop codon, remove an initiation codon, or cause a frameshift in the open reading frame. Such modifications may be made by site-directed mutagenesis or PCR-generated mutagenesis according to methods known in the art (see, for example, Botstein and Shortle, 1985; Lo et al., 1985; Higuchi et al., 1988; Shimada, 1996; Ho et al., 1989; Horton et al., 1989, and Sarkar and Sommer, 1990). Thus, in certain embodiments, genes of the present disclosure are inactivated by complete or partial deletion.

[0246] In another embodiment, modified Bacillus cells are constructed by the process of gene conversion (see, e.g., Iglesias and Trautner, 1983). For example, in gene conversion methods, a nucleic acid sequence corresponding to a gene is mutated in vitro to produce a defective nucleic acid sequence, which is then transformed into a parent Bacillus cell to produce the defective gene. By homologous recombination, the defective nucleic acid sequence replaces the endogenous gene. It may be desirable for the defective gene or gene fragment to also encode a marker that can be used to select for transformants containing the defective gene. For example, the defective gene can be introduced into a non-replicating or temperature-sensitive plasmid in association with a selectable marker. Selection for integrating the plasmid is achieved by marker selection under conditions that do not allow the plasmid to replicate. Selection of a second recombination event resulting in gene replacement is achieved by examining colonies for loss of the selectable marker and acquisition of a mutated gene (Perego, 1993). Alternatively, the defective nucleic acid sequence may contain an insertion, substitution or deletion of one or more nucleotides of the gene, as described below.

[0247] In other embodiments, modified Bacillus cells are constructed by established antisense technology using a nucleotide sequence that is complementary to the nucleic acid sequence of a gene (Parish and Stoker, 1997). More specifically, expression of a gene by a Bacillus cell can be reduced (downregulated) or eliminated by introducing a nucleotide sequence complementary to the nucleic acid sequence of the gene, which can be transcribed in the cell and hybridize to the mRNA produced in the cell. Under conditions that allow the complementary antisense nucleotide sequence to hybridize to the mRNA, the amount of protein translated is therefore reduced or eliminated. Such antisense methods include, but are not limited to, RNA interference (RNAi), small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, etc., all of which are well known to those skilled in the art.

[0248] In other embodiments, modified Bacillus cells are made / constructed by CRISPR-Cas9 editing. For example, genes encoding rghR1, rghR2, yvzC and / or Bli3644 may be disrupted (or deleted or downregulated) by guide RNA (e.g., Cas9) that recruits endonucleases to target sequences on DNA and nucleic acid-guided endonucleases that find their target DNA by binding to either Cpfl or guide DNA (e.g., NgAgo), where the endonucleases can generate single-strand or double-strand breaks in DNA. This targeted DNA break can be a substrate for DNA repair and recombine with the editing template provided to disrupt or delete the gene. For example, a gene encoding a nucleic acid-guided endonuclease (for this purpose, Cas9 from S. pyogenes) or a codon-optimized gene encoding a Cas9 nuclease is operably linked to a promoter active in a Bacillus cell and a terminator active in a Bacillus cell, thereby generating a Bacillus Cas9 expression cassette. Similarly, one or more target sites unique to a gene of interest can be readily identified by one of skill in the art. For example, to construct a DNA construct encoding a gRNA directed to a target site within a gene of interest using Streptococcus pyogenes Cas9, a variable targeting domain (VT) would contain the nucleotides of the target site that are 5' of a (PAM) protospacer adjacent motif (NGG), which nucleotides are fused to DNA encoding the Cas9 endonuclease recognition domain (CER) for S. pyogenes Cas9. Combination of the DNA encoding the VT domain with the DNA encoding the CER domain thereby generates DNA encoding the gRNA.Thus, a Bacillus expression cassette for a gRNA is generated by operably linking DNA encoding the gRNA to a promoter active in a Bacillus cell and a terminator active in a Bacillus cell.

[0249] In some embodiments, the DNA break induced by the endonuclease is repaired / replaced with the incoming sequence.For example, to precisely repair the DNA break generated by the above-mentioned Cas9 expression cassette and gRNA expression cassette, a nucleotide editing template is provided so that the DNA repair mechanism of the cell can utilize the editing template.For example, about 500 bp 5' of the targeting gene can be fused to about 500 bp 3' of the targeting gene to generate an editing template, which is used by the Bacillus host's mechanism to repair the DNA break generated by the RGEN.

[0250] The Cas9 expression cassette, the gRNA expression cassette and the editing template can be delivered simultaneously to cells using a number of different methods. Transformed cells are screened by PCR amplification of the target locus by amplifying the locus with forward and reverse primers. These primers can amplify the wild-type locus or the modified locus that has been edited by RGEN. These fragments are then sequenced using sequencing primers to identify edited colonies (see, for example, the Examples section below).

[0251] In yet other embodiments, the modified Bacillus cells are constructed by random or directed mutagenesis using methods well known in the art, including, but not limited to, chemical mutagenesis (see, e.g., Hopwood, 1970) and translocation (see, e.g., Youngman et al., 1983). Genetic modification may be performed by subjecting a parent cell to mutagenesis and screening for mutant cells in which expression of the gene is reduced or eliminated. Mutagenesis, which may be directed or random, may be performed, for example, by the use of suitable physical or chemical mutagenizing agents, by the use of suitable oligonucleotides, or by subjecting the DNA sequence to PCR-generated mutagenesis. Moreover, this mutagenesis may be performed by using any combination of these mutagenesis methods.

[0252] Examples of physical or chemical mutagenic agents suitable for the present invention include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), N-methyl-N'-nitrosoguanidine (NTG), O-methylhydroxylamine, nitrous acid, ethyl methanesulfonate (EMS), sodium bisulfite, formic acid and nucleotide analogs. When such agents are used, mutagenesis is typically carried out by incubating parent cells to be mutagenized under suitable conditions in the presence of the mutagenizing agent of choice, and selecting mutant cells that show reduced or no expression of the gene.

[0253] WO 2003 / 083125 discloses methods for modifying Bacillus cells, such as creating Bacillus deletion strains and DNA constructs using PCR fusion to bypass E. coli. WO 2002 / 14490 discloses methods for modifying Bacillus cells, including (1) construction and transformation of an integrative plasmid (pComK), (2) random mutagenesis of coding, signal and propeptide sequences, (3) homologous recombination, (4) increasing transformation efficiency by adding non-homologous flanks to the transforming DNA, (5) optimizing double crossover integration, (6) site-directed mutagenesis, and (7) markerless deletion.

[0254] Those skilled in the art are familiar with suitable methods for introducing polynucleotide sequences into bacterial cells (e.g., E. coli and Bacillus species) (see, e.g., Ferrari et al., 1989; Saunders et al., 1984; Hoch et al., 1967; Mann et al., 1986; Holubova, 1985; Chang et al., 1979; Vorobjeva et al., 1980; Smith et al., 1986; Fisher et al., 1981 and McDonald, 1984). Indeed, methods such as transformation, including protoplast transformation and conjugation, transduction, and protoplast fusion, are known and suitable for use in the present disclosure. Transformation methods are particularly preferred for introducing the DNA constructs of the present disclosure into host cells.

[0255] In addition to commonly used methods, in some embodiments, the host cell is directly transformed (i.e., no intermediate cell is used to amplify or otherwise process the DNA construct prior to introduction into the host cell). Introduction of the DNA construct into the host cell includes those physical and chemical methods known in the art for introducing DNA into a host cell without insertion into a plasmid or vector. Such methods include, but are not limited to, calcium chloride precipitation, electroporation, naked DNA, liposomes, and the like. In additional embodiments, the DNA construct is co-transformed with a plasmid without insertion into a plasmid. In further embodiments, the selection marker is deleted or substantially excised from the modified Bacillus strain by methods known in the art (e.g., Stahl et al., 1984; Palmeros et al., 2000). In some embodiments, degradation of the vector from the host chromosome leaves flanking regions in the chromosome while removing the unique chromosomal region.

[0256] Promoters and promoter sequences, their open reading frames (ORFs) and / or variants thereof for use in expressing genes in Bacillus cells are generally known to those of skill in the art. The promoter sequences of the present disclosure are generally selected such that they are functional in Bacillus cells. Certain exemplary Bacillus promoter sequences include, but are not limited to, the B. subtilis alkaline protease (aprE) promoter, the B. subtilis α-amylase promoter, the B. amyloliquefaciens α-amylase promoter, the neutral protease (nprE) promoter from B. subtilis, the mutant aprE promoter (e.g., WO 2001 / 51643) or any other promoter from B. licheniformis or other related Bacilli. Methods for screening and generating promoter libraries with a wide range of activity (promoter strength) in Bacillus cells are described in WO 2003 / 089604.

[0257] V. Culturing the Modified Cells to Produce a Protein of Interest As generally described above, certain other embodiments relate to compositions and methods for constructing and obtaining Bacillus cells / strains with increased protein production phenotypes. Accordingly, certain embodiments relate to methods for producing a protein of interest in Bacillus cells by fermenting / cultivating the cells in a suitable medium. Fermentation methods well known in the art can be applied to ferment the parent and modified (daughter) Bacillus cells of the present disclosure.

[0258] In some embodiments, the cells are cultured under batch or continuous fermentation conditions. Classical batch fermentation is a closed system in which the composition of the medium is set at the beginning of the fermentation and does not change during the fermentation. At the beginning of the fermentation, the medium is inoculated with the desired organism. In this method, fermentation is allowed to occur without adding any components to the system. Typically, batch fermentation is considered to be "batch" with respect to the addition of the carbon source, and factors such as pH and oxygen concentration are often controlled. The metabolic products and biomass composition of a batch system are constantly changing until the point at which the fermentation is stopped. In a typical batch culture, cells may progress through a static lag phase to a high growth log phase and eventually to a stationary phase where the growth rate is reduced or stopped. If not treated, the cells in the stationary phase will eventually die. Generally, the cells in the log phase are responsible for the mass production of the product.

[0259] A suitable variation to the standard batch system is the "fed-batch fermentation" system. In this variation of the typical batch system, substrate is added gradually as the fermentation progresses. Fed-batch systems are useful when catabolite repression is likely to inhibit the metabolism of the cells and when a limited amount of substrate in the medium is desired. In fed-batch systems, the actual substrate concentration is difficult to measure and is therefore estimated based on changes in measurable factors such as pH, dissolved oxygen, and partial pressure of waste gases such as CO2. Batch and fed-batch fermentation are common and known in the art.

[0260] Continuous fermentation is an open system in which a defined fermentation medium is continuously added to a bioreactor and an equal amount of conditioned medium is simultaneously removed for processing. Continuous fermentation generally maintains the culture at a constant high density where the cells are primarily in logarithmic growth phase. Continuous fermentation allows for the adjustment of one or more factors that affect cell growth and / or product concentration. For example, in one embodiment, the limiting nutrient, such as the carbon or nitrogen source, is maintained at a constant ratio while all other parameters can be adjusted. In other systems, many factors that affect growth can be continuously varied while the cell concentration, measured by the turbidity of the medium, is kept constant. Continuous systems attempt to maintain steady-state growth conditions. Thus, cell loss due to medium removal must be balanced against the cell growth rate during fermentation. Methods for adjusting nutrients and growth factors in continuous fermentation processes, as well as techniques for maximizing the rate of product formation, are well known in the art of industrial microbiology.

[0261] In certain embodiments, the protein of interest expressed / produced by the Bacillus cells of the present disclosure can be recovered from the culture medium by separating the host cells from the medium by centrifugation or filtration, or, if necessary, by disrupting the cells and removing the supernatant from the cell fraction and cell debris. Typically, after clarification, the protein component of the supernatant or filtrate is precipitated by a salt, e.g., ammonium sulfate. The precipitated protein can then be solubilized and purified by various chromatographic methods, e.g., ion exchange chromatography, gel filtration.

[0262] VI. Proteins of Interest The protein of interest (POI) of the present disclosure may be any endogenous or heterologous protein, or a variant of such a POI. The protein may contain one or more disulfide bridges, or may be a protein whose functional form is monomeric or multimeric, i.e., the protein has a quaternary structure and is composed of multiple identical (homologous) or non-identical (heterologous) subunits, where the POI or variant POI is preferably a protein with a property of interest. For example, in certain embodiments, the modified Bacillus cells of the present disclosure produce at least about 0.5% more, at least about 1% more, at least about 5% more, at least about 6% more, at least about 7% more, at least about 8% more, at least about 9% more, or at least about 10% or more of the POI compared to its unmodified (parent) cell.

[0263] In certain embodiments, the modified Bacillus cells of the present disclosure exhibit increased specific productivity (Qp) of the POI compared to the (unmodified) parent Bacillus cell. For example, detection of specific productivity (Qp) is a suitable method for assessing protein production. Specific productivity (Qp) is calculated according to the following equation: "Qp = gP / gDCW·hr" (where "gP" is grams of protein produced in the tank, "gDCW" is grams of dry cell weight (DCW) in the tank, and "hr" is the fermentation time (hours) from the time of inoculation, which includes the production time and the growth time.) can be determined using

[0264] Thus, in certain other embodiments, the modified Bacillus cells of the present disclosure comprise an increase in specific productivity (Qp) of at least about 0.1%, at least about 1%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10% or more compared to the unmodified (parent) cell.

[0265] In certain embodiments, the POI or a variant thereof is an acetyl esterase, an aminopeptidase, an amylase, an arabinase, an arabinofuranosidase, a carbonic anhydrase, a carboxypeptidase, a catalase, a cellulase, a chitinase, a chymosin, a cutinase, a deoxyribonuclease, an epimerase, an esterase, an α-galactosidase, a β-galactosidase, an α-glucanase, a glucan lyase, a glycan ... lysases), endo-β-glucanase, glucoamylase, glucose oxidase, α-glucosidase, β-glucosidase, glucuronidase, glycosyl hydrolase, hemicellulase, hexose oxidase, hydrolase, invertase, isomerase, laccase, ligase, lipase, lyase, mannosidase, oxidase, oxidoreductase, pectate lyase, pectin acetyl esterase, pectin depolymerase, pectin methyl esterase, pectin degrading enzyme, perhydrolase, polyol oxidase, peroxidase, phenol oxidase, phytase, polygalacturonase, protease, peptidase, rhamno-galacturonase, ribonuclease, transferase, transport protein, transglutaminase, xylanase, hexose oxidase, and combinations thereof.

[0266] Thus, in certain embodiments, the POI or variant POI thereof is an enzyme selected from Enzyme Code (EC) EC1, EC2, EC3, EC4, EC5 or EC6.

[0267] In certain other embodiments, the modified Bacillus cells of the present disclosure comprise an expression construct encoding an amylase. A wide variety of amylase enzymes and variants thereof are known to those of skill in the art. For example, WO 2006 / 037484 and WO 2006 / 037483 describe mutant α-amylases with improved solvent stability, WO 1994 / 18314 discloses oxidatively stable α-amylase variants, WO 1999 / 19467, WO 2000 / 29560 and WO 2000 / 60059 disclose Termamyl-like α-amylase variants, and WO 2008 / 112459 discloses mutant α-amylases having improved solvent stability, WO 2006 / 037483 ... sp. 707, WO 1999 / 43794 discloses maltogenic α-amylase variants, WO 1990 / 11352 discloses hyperthermostable α-amylase variants, and WO 2006 / 089107 discloses α-amylase variants with granular starch hydrolyzing activity.

[0268] There are a variety of assays known to those of skill in the art to detect and measure the activity of intracellularly and extracellularly expressed proteins.

[0269] WO 2014 / 164777 discloses a Ceralpha α-amylase activity assay useful for detecting the amylase activity described herein. EXAMPLES

[0270] Certain aspects of the present invention can be further understood in light of the following examples, which should not be construed as limiting. Modifications of materials and methods will be apparent to those skilled in the art.

[0271] Example 1 Construction of CAS9 vector targeting the RGHR locus The Cas9 protein from S. pyogenes (SEQ ID NO:1) was codon-optimized for Bacillus (SEQ ID NO:2) with the addition of an N-terminal nuclear localization sequence (NLS, "APKKKRKV"; SEQ ID NO:3), a C-terminal NLS ("KKKKLK"; SEQ ID NO:4) and a deca-histidine tag ("HHHHHHHHHH"; SEQ ID NO:5), the aprE promoter sequence (SEQ ID NO:6) and terminator sequence (SEQ ID NO:7) from B. subtilis, and amplified using Q5 DNA polymerase (NEB) with the forward (SEQ ID NO:8) and reverse (SEQ ID NO:9) primer pairs shown in Table 1 below, according to the manufacturer's instructions. [Table 1]

[0272] The backbone (SEQ ID NO:10) of plasmid pKB320 (SEQ ID NO:11) was amplified using Q5 DNA polymerase (NEB) with the forward (SEQ ID NO:12) and reverse (SEQ ID NO:13) primer pairs shown in Table 2 below, according to the manufacturer's instructions. [Table 2]

[0273] The PCR products were purified using Zymo clean and concentrate 5 columns according to the manufacturer's instructions. The PCR products were then assembled by long overlap extension PCR (POE-PCR) using Q5 polymerase (NEB) by mixing the two fragments in an equimolar ratio. The following POE-PCR reaction cycles were performed: 98°C for 5 s, 64°C for 10 s, and 72°C for 4 min 15 s for 30 cycles. Five microliters of POE-PCR (DNA) was transformed into Top10 E. coli (Invitrogen) according to the manufacturer's instructions and selected on lysogeny (L) broth (Miller's formulation; 1% w / v tryptone, 0.5% w / v yeast extract, 1% w / v NaCl) containing 50 μg / mL kanamycin sulfate and solidified with 1.5% agar. Colonies were grown at 37°C for 18 h. Colonies were picked and plasmid DNA was prepared using a Qiaprep DNA miniprep kit according to the manufacturer's instructions and eluted in 55 μL of ddH2O. The plasmid DNA was Sanger sequenced to confirm correct assembly using the sequencing primer sets shown in Table 3 below. [Table 3]

[0274] The correctly assembled plasmid pRF694 (SEQ ID NO:25) was used to construct plasmids pRF801 (SEQ ID NO:26) and pRF806 (SEQ ID NO:27) for editing the B. licheniformis genome at target site 1 (TS1; SEQ ID NO:28) and target site 2 (TS2; SEQ ID NO:29), as described below.

[0275] The serA1 open reading frame of B. licheniformis (SEQ ID NO: 30) contains a unique target site (TS) target site 1 (TS1; SEQ ID NO: 28) in the reverse orientation. TS1 is adjacent to a proto-spacer adjacent motif (PAM; SEQ ID NO: 31) in the reverse orientation. The target site can be converted to DNA encoding a variable targeting (VT) domain (SEQ ID NO: 32). The DNA sequence encoding the VT domain (SEQ ID NO: 32) is operably fused to a DNA sequence encoding a Cas9 endonuclease recognition domain (CER, SEQ ID NO: 33) to produce a functional guide RNA (gRNA) (SEQ ID NO: 34) that targets target site 1 when transcribed by a bacterial cell RNA polymerase. The DNA encoding the gRNA was operably linked to a promoter operable in a Bacillus sp. cell (e.g., the spac promoter; SEQ ID NO: 35) and a terminator sequence operable in a Bacillus sp. cell (e.g., the t0 terminator sequence of lambda phage; SEQ ID NO: 36) such that the promoter was located 5' of the DNA encoding the gRNA (SEQ ID NO: 33) and the terminator was located 3' of the DNA encoding the gRNA (SEQ ID NO: 33).

[0276] An editing template for deleting the serA1 gene in response to Cas9 / gRNA cleavage was generated by amplification of two homology arms from B. licheniformis genomic DNA (gDNA). The first fragment (homology arm 1) corresponds to the 500 nucleotides immediately upstream (5') of the serA1 ORF (SEQ ID NO:37). This fragment was amplified using Q5 DNA polymerase (NEB) according to the manufacturer's instructions and the forward (SEQ ID NO:38) and reverse (SEQ ID NO:39) primers listed in Table 4 below. These primers incorporate 18 nucleotides on the 3' end of the first fragment that are homologous to the 5' end of the second fragment and 20 nucleotides at the 5' end of the first fragment that are homologous to pRF694. [Table 4]

[0277] The second fragment (homology arm 2) corresponds to 500 nucleotides immediately downstream of the 3' end of the serA1 ORF (SEQ ID NO:40). This fragment was amplified using Q5 DNA polymerase and the forward (SEQ ID NO:41) and reverse (SEQ ID NO:42) primers listed in Table 5 below, according to the manufacturer's instructions. These primers incorporate 28 nucleotides on the 5' end of the second fragment that are homologous to the 3' end of the first fragment and 21 nucleotides on the 3' end of the second fragment that are homologous to pRF694. [Table 5]

[0278] DNA encoding the gRNA expression cassette for target site 1 (SEQ ID NO: 43), the first homology arm (SEQ ID NO: 37) and the second homology arm (SEQ ID NO: 40) were assembled in pRF694 (SEQ ID NO: 25) using standard molecular biology techniques to assemble plasmid pRF801 (SEQ ID NO: 26), an E. coli-B. licheniformis shuttle plasmid containing a Cas9 expression cassette (SEQ ID NO: 2), a gRNA expression cassette encoding a gRNA targeting TS1a in the serA1 ORF (SEQ ID NO: 43) and an editing template (SEQ ID NO: 44) consisting of the first homology arm (SEQ ID NO: 37) and the second homology arm (SEQ ID NO: 40). Plasmids were verified by Sanger sequencing using the oligonucleotides (primers) shown in Table 3 above.

[0279] The rghR1 open reading frame of B. licheniformis (SEQ ID NO: 45) contains a unique target site (TS) on the reverse strand, target site 2 (TS2; SEQ ID NO: 28). This target site is adjacent to a proto-spacer adjacent motif (PAM; SEQ ID NO: 46) on the reverse strand. This target site can be converted to DNA encoding a variable targeting (VT) domain (SEQ ID NO: 47). The DNA sequence encoding the VT domain (SEQ ID NO: 47) is operably fused to a DNA sequence encoding a Cas9 endonuclease recognition domain (CER; SEQ ID NO: 33) to produce a functional gRNA (gRNA) (SEQ ID NO: 48) that targets target site 2 when transcribed by a bacterial cell RNA polymerase. The DNA encoding the gRNA was operably linked to a promoter operable in a Bacillus sp. cell (e.g., the spac promoter from B. subtilis, SEQ ID NO:35) and a terminator operable in a Bacillus sp. cell (e.g., the t0 terminator sequence of lambda phage; SEQ ID NO:36) such that the promoter was located 5' of the DNA encoding the gRNA (SEQ ID NO:48) and the terminator was located 3' of the DNA encoding the gRNA (SEQ ID NO:48).

[0280] An editing template for modifying the rghR1 gene in response to Cas9 / gRNA cleavage was generated by amplification of two homology arms from B. licheniformis genomic DNA (gDNA). The first fragment corresponds to the 500 nucleotides immediately upstream (5') of the rghR1 ORF (homology arm 1; SEQ ID NO:49). This fragment was amplified using Q5 DNA polymerase (NEB) and the forward (SEQ ID NO:50) and reverse (SEQ ID NO:51) primers listed in Table 6 below, according to the manufacturer's instructions. These primers incorporate 23 nucleotides on the 3' end of the first fragment that are homologous to the 5' end of the second fragment and 20 nucleotides at the 5' end of the first fragment that are homologous to pRF694. [Table 6]

[0281] The second fragment corresponds to 500 nucleotides immediately downstream of the 3' end of the rghR1 ORF (homology arm 2; SEQ ID NO:52). This fragment was amplified using Q5 DNA polymerase and the forward (SEQ ID NO:53) and reverse (SEQ ID NO:54) primers listed in Table 7 below, according to the manufacturer's instructions. These primers incorporate 20 nucleotides on the 5' end of the second fragment that are homologous to the 3' end of the first fragment and 21 nucleotides on the 3' end of the second fragment that are homologous to pRF694. [Table 7]

[0282] DNA encoding the gRNA expression cassette (SEQ ID NO:55), first homology arm (SEQ ID NO:49) and second homology arm (SEQ ID NO:52) for target site 2 was assembled in pRF694 (SEQ ID NO:25) using standard molecular biology techniques to construct pRF806 (SEQ ID NO:27), an E. coli-B. licheniformis shuttle plasmid containing a Cas9 expression cassette (SEQ ID NO:2), a plasmid pRF694 (SEQ ID NO:25) containing a gRNA expression cassette (SEQ ID NO:55) encoding gRNA target site 2 within the rghR1 ORF and an editing template (SEQ ID NO:56) consisting of the first homology arm (SEQ ID NO:49) and the second homology arm (SEQ ID NO:52). The plasmid was verified by Sanger sequencing using the oligonucleotides (primers) shown in Table 3 above.

[0283] Example 2 Construction of CAS9 Y155H mutant and related targeting plasmids In this example, the S. pyogenes Cas9 (SEQ ID NO:57) Y155H mutant was constructed in pRF801 (SEQ ID NO:26) and pRF806 plasmids (SEQ ID NO:27). To introduce the (Cas9) Y155H mutant into the pRF801 (SEQ ID NO:26) or pRF806 (SEQ ID NO:27) plasmids, site-directed mutagenesis was performed using the Quikchange mutagenesis kit and the pRF801 (SEQ ID NO:26) or pRF806 (SEQ ID NO:27) plasmid as template DNA according to the manufacturer's instructions, using the forward (SEQ ID NO:58) and reverse (SEQ ID NO:59) primers shown in Table 8 below. [Table 8]

[0284] The resulting reaction product, pRF827 (SEQ ID NO:60), contained an editing template (SEQ ID NO:44) composed of a (Cas9) Y155H mutant expression cassette (SEQ ID NO:61), a gRNA expression cassette (SEQ ID NO:43) encoding gRNA targeting site 1 (TS1) in the serA1 ORF, and a first (SEQ ID NO:37) and a second (SEQ ID NO:40) homology arm; or pRF856 (SEQ ID NO:62) composed of a (Cas9) Y155H mutant expression cassette (SEQ ID NO:61), a gRNA expression cassette (SEQ ID NO:55) targeting site 2 (TS2) in the rghR1 ORF, and a first (SEQ ID NO:49) and a second (SEQ ID NO:52) homology arm. These plasmid DNAs were Sanger sequenced to verify correct assembly using the sequencing primers (primers) shown in Table 3 above.

[0285] Construction of plasmid pRF862 Plasmid pRF862 (SEQ ID NO:77) was constructed by transferring a fragment of the Cas9 ORF (SEQ ID NO:63) containing the Y155H (mutant) substitution from pRF827 (SEQ ID NO:60) and amplified using the forward (SEQ ID NO:64) and reverse (SEQ ID NO:65) primers shown in Table 9 below. [Table 9]

[0286] The second fragment (SEQ ID NO:67) was amplified from pRF694 (SEQ ID NO:66) such that it contains the entire plasmid except for the fragment contained on the pRF827 fragment (SEQ ID NO:60) above. This fragment shares homology with the 5' and 3' ends of the pRF827 fragment (SEQ ID NO:60) for assembly purposes and was amplified using the forward (SEQ ID NO:68) and reverse (SEQ ID NO:69) primers listed in Table 10 below. [Table 10]

[0287] The two fragments were assembled using NEBuilder according to the manufacturer's instructions and transformed into E. coli competent cells. The plasmid sequence was verified by Sanger sequencing using the oligonucleotides (primers) shown in Table 3 above. A sequence verified isolate was saved as plasmid pRF862 (SEQ ID NO: 77).

[0288] pRF869 (SEQ ID NO:70), a plasmid targeting the rghR2 ORF (SEQ ID NO:71) and inserting three in-frame stop codons, was constructed using two parts. The first part (SEQ ID NO:72), containing an editing template (SEQ ID NO:73) for modifying the rghR2 ORF (SEQ ID NO:71) and a gRNA expression cassette (SEQ ID NO:74) targeting the rghR2 ORF (SEQ ID NO:71), was synthesized by IDT and amplified for assembly using the forward (SEQ ID NO:75) and reverse (SEQ ID NO:76) primers shown in Table 11 below. [Table 11]

[0289] The second part (SEQ ID NO: 77) from pRF862 (SEQ ID NO: 77) containing the Cas9 expression cassette and all plasmid components were amplified using the forward (SEQ ID NO: 78) and reverse (SEQ ID NO: 79) primers shown in Table 12 below. [Table 12]

[0290] These two parts were assembled using NEBuilder according to the manufacturer's instructions and transformed into E. coli. The plasmid sequence was verified by Sanger sequencing using the oligonucleotides (primers) shown in Table 3 above. The sequence verified isolate was saved as pRF869 (SEQ ID NO: 70).

[0291] Several additional Cas9 plasmids were constructed as described above in Examples 1 and 2. The plasmids are listed below in Table 13, along with their target site (TS) sequences and editing template functions. As used in Table 13 below, the term "SID" is an abbreviation for "Sequence" number. [Table 13]

[0292] Example 3 CONSTRUCTION OF AMYLASE EXPRESSING BACILLUS STRAINS CONTAINING VARIOUS RGHR LOCUS ALLELES In this example, a series of rghR locus alleles were introduced into a parent B. licheniformis strain that contains an expression cassette encoding a mutant Cytophaga sp. α-amylase (e.g., a mutant Cytophaga sp. α-amylase described in WO 2017 / 100720, which is incorporated by reference in its entirety). More specifically, the parent B. licheniformis strain, designated LDN143, contains (a) a native rghR locus, (b) a deletion of the serA gene (SEQ ID NO: 30), a deletion of the lysA gene (SEQ ID NO: 92), and two α-amylase expression cassettes.

[0293] For example, the first expression cassette (SEQ ID NO: 93) integrated within the serA locus comprises the serA ORF (SEQ ID NO: 30) operably linked to DNA encoding the B. subtilis aprE 5'-UTR (SEQ ID NO: 95) operably linked to DNA encoding the B. licheniformis amyL signal sequence (SEQ ID NO: 96) operably linked to a DNA sequence encoding a Cytophaga sp. mutant alpha amylase (SEQ ID NO: 97) operably linked to a DNA sequence encoding a Cytophaga sp. operably linked to a B. licheniformis amyL transcription terminator (SEQ ID NO: 98), and a synthetic p3 promoter (SEQ ID NO: 94 as described in WO 2017 / 152169). The second expression cassette (SEQ ID NO:99) integrated within the amyL locus comprises a lysA auxotrophic marker (SEQ ID NO:92) operably linked to DNA encoding the B. subtilis aprE 5'-UTR (SEQ ID NO:95) operably linked to DNA encoding the amyL signal sequence (SEQ ID NO:96) operably linked to a DNA sequence encoding a Cytophaga sp. mutant alpha-amylase (SEQ ID NO:97) operably linked to the B. licheniformis amyL transcription terminator (SEQ ID NO:98), and the B. licheniformis amyL promoter (SEQ ID NO:100).

[0294] A version of LDN143 cells / strains containing the pBl.comK plasmid (SEQ ID NO:101) containing a spectinomycin marker (SEQ ID NO:102), DNA encoding the XylR repressor (SEQ ID NO:103) and the xylA promoter (SEQ ID NO:104) operably linked to DNA encoding the B. licheniformis ComK protein (SEQ ID NO:105) (see, e.g., Liu and Zuber, 1998; Hamoen et al., 1998; U.S. Patent Application Publication No. 2006 / 0199222) were transformed with pRF869 (SEQ ID NO:70), pRF874 (SEQ ID NO:80), pRF879 (SEQ ID NO:83), pRF899 (SEQ ID NO:86) or pRF901 (SEQ ID NO:89) plasmids using rolling circle amplification (TruePrime RCA, Lucigen).

[0295] Briefly, LDN143 / pBl.comK competent cells were generated. The LDN143 / pBl.comK strain was grown overnight in L broth containing 100 ppm spectinomycin at 37° C. with shaking at 250 RPM. The culture reached an OD of 0.7 in fresh L broth containing 100 ppm spectinomycin. 600The new culture was grown for 1 hour at 37°C and 250 rpm. D-Xylose was added to 0.1% w / v and the culture was grown for an additional 4 hours. The cells were harvested at 1700g for 7 minutes. The cells were resuspended in one-quarter culture volume of spent medium containing 10% w / v DMSO. 100 μL of cells were mixed with 10 μL of plasmid RCA amplification product of pRF869 (SEQ ID NO:70), pRF874 (SEQ ID NO:80), pRF879 (SEQ ID NO:83), pRF899 (SEQ ID NO:86) or pRF901 (SEQ ID NO:89). The cell / DNA mixture was incubated for 1.5 hours at 37°C and 1400 RPM. The mixture was then plated on L agar plates containing 20 ppm kanamycin. The inoculated plates were incubated at 37°C for 48-72 hours. Colonies formed on L agar containing 20 ppm kanamycin were screened using colony PCR to confirm modification of the locus as described below.

[0296] For cells transformed with pRF869 (SEQ ID NO:70), the rghR2 gene was amplified using standard PCR techniques with the forward (SEQ ID NO:106) and reverse (SEQ ID NO:107) primers listed in Table 14 below. [Table 14]

[0297] This PCR product, a 1,164 nucleotide fragment containing the targeted region of rghR2 (SEQ ID NO:108), was amplified to generate a PCR product of rghR2 containing three in-frame nonsense mutations using the forward (SEQ ID NO:110) primer shown in Table 15 below. stop The allele (SEQ ID NO: 109) was sequenced using the Sanger method to confirm the introduction of the allele. rghR2 stop The isolate carrying the allele (SEQ ID NO: 109) was preserved as strain BF314. [Table 15]

[0298] For cells transformed with pRF874 (SEQ ID NO:80), the rghR1 gene region was amplified using the forward (SEQ ID NO:111) and reverse (SEQ ID NO:112) primers shown in Table 16 below. [Table 16]

[0299] The native rghR1 fragment (SEQ ID NO:113) produced by the primers in Table 16 is 1,499 nucleotides in length. When the rghR1 gene is deleted (ΔrghR1), the fragment produced by the primers in Table 16 (SEQ ID NO:114) is 1,097 nucleotides in length, apparently shorter on electrophoresis. An isolate of LDN143 containing the deleted rghR1 allele (ΔrghR1; SEQ ID NO:114) was kept as strain BF324.

[0300] For cells transformed with pRF879 (SEQ ID NO:83), the rghR2 locus was amplified using the forward (SEQ ID NO:115) and reverse (SEQ ID NO:116) primers shown in Table 17 below. [Table 17]

[0301] The native rghR2 fragment (SEQ ID NO:117) produced by the primers in Table 17 is 1,629 nucleotides in length. When the rghR2 gene is deleted (ΔrghR2), the fragment (SEQ ID NO:118) produced by the primers in Table 17 is 1,248 nucleotides in length, electrophoretically apparently shorter. An isolate of LDN143 containing the rghR2 locus allele (SEQ ID NO:118) was saved as strain BF377.

[0302] For cells transformed with pRF899 (SEQ ID NO:86), the rghR2 rghR1 region was amplified using the forward (SEQ ID NO:119) and reverse (SEQ ID NO:120) primers shown in Table 18 below. [Table 18]

[0303] The native rghR2rghR1 fragment (SEQ ID NO:121) produced from parent strain LDN143 with the primers in Table 18 is 2,353 nucleotides in length. When the rghR2 and rghR1 genes are deleted (ΔrghR2 ΔrghR1), the fragment produced with the primers in Table 18 (SEQ ID NO:122) is 1,401 nucleotides in length, electrophoretically apparently shorter. An isolate of LDN143 containing the ΔrghR2 gene ΔrghR1 allele (SEQ ID NO:122) was kept as strain BF389.

[0304] For cells transformed with pRF901 (SEQ ID NO:89), the rghR2 locus was amplified using the forward (SEQ ID NO:123) and reverse (SEQ ID NO:124) primers shown in Table 19 below. [Table 19]

[0305] The native rghR2 fragment (SEQ ID NO:125) generated from the parent strain LDN143 with the primers in Table 19 is 3,265 nucleotides in length. When the rghR2, rghR1, yvzC, and 3644 genes are deleted (ΔrghR2, ΔrghR1, ΔyvzC, and Δ3644), the fragment generated with the primers in Table 19 (SEQ ID NO:126) is 1,596 nucleotides in length, electrophoretically evidently shorter. An isolate of LDN143 containing the ΔrghR2, ΔrghR1, ΔyvzC, and Δ3644 alleles was saved as BF391.

[0306] Example 4 Production of amylase in Bacillus strains containing modified RGHR locus To determine the effect of various rghR locus alleles on α-amylase production, strains were grown in triplicate under standard small-scale assay conditions as generally described in WO 2018 / 156705 (hereby incorporated by reference in its entirety). Yields of mutant (Cytophaga sp.) α-amylase were determined by using the Bradford protein assay (Peirce) according to the manufacturer's instructions. The average α-amylase production for each strain was therefore determined as shown in Table 20 below and normalized to the parent strain LDN143. [Table 20]

[0307] Thus, as shown in Table 20, B. licheniformis cells / strains with mutations at the rghR locus demonstrate increased production of approximately 23-62% more heterologous amylase protein than comparable parental cells (LDN143) that are wild-type for the rghR locus.

[0308] Example 5 Pulcherimin production in Bacillus strains with modified RGHR locus As briefly described in section III above, a particular feature of the rghR locus is the transcriptional control of the operon responsible for producing the iron-scavenging pigment pulcherrimic acid. For example, pulcherrimic acid is known to react extracellularly with iron ions to produce an insoluble red pigment that can be resolubilized as the sodium salt and quantified using absorbance at 410 nm (Uffen and Canale-Parola, 1972). Briefly, 10 mL of culture supernatant was harvested at 4000 RPM for 10 minutes. The pellet was washed twice with water. The pellet was resuspended in 1 mL of 1N NaOH and incubated at room temperature for 10 minutes to convert the insoluble pulcherrimin to soluble sodium pulcherrimate. Residual debris was removed by brief centrifugation at 14000 RPM. The absorbance at 410 nm was measured against a 1N NaOH blank. [Table 21]

[0309] Thus, as shown in Table 21 above, several mutations at the rghR locus significantly reduced pulcherrimin production by about 30-50% compared to the parent (e.g., BF314 and BF377), while several other mutations increased pulcherrimin production by about 10-20% compared to the parent (e.g., BF324, BF389, and BF391), indicating that mutations at the rghR locus control the biosynthesis of pulcherrimic acid.

[0310] To determine the relative yield of biosynthesis for the various strains while producing the heterologous amylase protein, the optical density (OD) of 200 μL of culture was measured at 600 nm, as presented in Table 22 below. [Table 22]

[0311] References PCT International Publication No. 1994 / 18314 PCT International Publication No. 1999 / 19467 PCT International Publication No. 1999 / 43794 PCT International Publication No. 2000 / 29560 PCT International Publication No. 2000 / 60059 PCT International Publication No. 2004 / 011609 PCT International Publication No. 2006 / 037483 PCT International Publication No. 2006 / 037484 PCT International Publication No. 2006 / 089107 PCT International Publication No. 2008 / 112459 PCT International Publication No. 2014 / 164777 PCT International Publication No. 2018 / 156705 Albertini and Galizzi, Bacteriol., 162:1203-1211, 1985. Bergmeyer et al., “Methods of Enzymatic Analysis” vol. 5, Peptidases, Proteinases and their Inhibitors, Verlag Chemie, Weinheim, 1984. Botstein and Shortle, Science 229:4719, 1985. Brode et al., “Subtilisin BPN'variants: increased hydrolytic activity on surface-bound substrates via decreased surface activity”, Biochemistry, 35(10):3162-3169, 1996. Caspers et al.,“Improvement of Sec-dependent secretion of a heterologous model protein in Bacillus subtilis by saturation mutagenesis of the N-domain of the AmyE signal peptide”,Appl.Microbiol.Biotechnol.,86(6):1877-1885,2010. Chang et al.,Mol.Gen.Genet.,168:11-115,1979. Christianson et al.,Anal.Biochem.,223:119-129,1994. Devereux et a / .,Nucl.Acid Res.,12:387-395,1984. Earl et al.,“Ecology and genomics of Bacillus subtilis”,Trends in Microbiology.,16(6):269-275,2008. Ferrari et al.,“Genetics,”in Harwood et al.(ed.), Bacillus,Plenum Publishing Corp.,1989. Fisher et.al.,Arch.Microbiol.,139:213-217,1981. Guerot-Fleury,Gene,167:335-337,1995. Hamoen et al.,“Controlling competence in Bacillus subtilis:shared used of regulators”,Microbiology,149:9-17,2003. Hamoen et al.,Genes Dev.12:1539-1550,1998. Hampton et al.,Seroloαical Methods,A Laboratory Manual,APS Press,St.Paul,MN,1990. Hardwood and Cutting(eds.)Molecular Biological Methods for Bacillus,John Wiley & Sons,1990. Hayashi et al.,2006 Hayashi et al.,Mol.Microbiol.,59(6):1714-1729,2006 Higuchi et al.,Nucleic Acids Research 16:7351,1988. Ho et al.,Gene 77:61,1989. Hoch et al.,J.Bacteriol.,93:1925-1937,1967. Holubova,Folia Microbiol.,30:97,1985. Hopwood,The Isolation of Mutants in Methods in Microbiology (J.R.Norris and D.W.Ribbons,eds.) pp 363-433,Academic Press,New York,1970. Horton et al.,Gene 77:61,1989. Hsia et al.,Anal Biochem.,242:221-227,1999. Iglesias and Trautner,Molecular General Genetics 189:73-76,1983. Jensen et al.,“Cell-associated degradation affects the yield of secreted engineered and heterologous proteins in the Bacillus subtilis expression system”Microbiology,146(Pt 10:2583-2594,2000. Liu and Zuber,1998, Lo et al.,Proceedings of the National Academy of Sciences USA 81:2285,1985. Maddox et al.,J.Exp.Med.,158:1211,1983. Mann et al.,Current Microbiol.,13:131-135,1986. McDonald,J.Gen.Microbiol.,130:203,1984. MacDonald,“Biosynthesis of pulcherriminic acid”,Biochem.J.,96:533-538,1965. Needleman and Wunsch,J.Mol.Biol.,48:443,1970. Ogura & Fujita,FEMS Microbiol Lett.,268(1):73-80. 2007. Olempska-Beer et al.,“Food-processing enzymes from recombinant microorganisms--a review”’Regul. Toxicol. Pharmacol.,45(2):144-158,2006. Palmeros et al.,Gene 247:255-264,2000. Parish and Stoker,FEMS Microbiology Letters 154:151-157,1997. Pearson and Lipman,Proc.Natl.Acad. Sci. USA 85:2444,1988. Perego,1993,In A.L.Sonneshein,J.A.Hoch,and R. Losick,editors,Bacillus subtilis and Other Gram-Positive Bacteria,Chapter 42,American Society of Microbiology,Washington,D.C. Raul et al.,“Production and partial purification of alpha amylase from Bacillus subtilis (MTCC 121) using solid state fermentation”,Biochemistry Research International,2014. Sarkar and Sommer,BioTechniques 8:404,1990. Saunders et al., J.Bacteriol.,157:718-726,1984. Shimada,Meth. Mol. Biol. 57:157;1996 Smith and Waterman,Adv. Appl. Math.,2:482,1981. Smith et al.,Appl. Env. Microbiol.,51:634 1986. Stahl and Ferrari, J. Bacteriol.,158:411-418,1984. Stahl et al,J.Bacteriol.,158:411-418,1984. Tarkinen,et al,J.Biol.Chem.258:1007-1013,1983. Trieu-Cuot et al.,Gene,23:331-341,1983. Uffen and Canale-Parola,“Synthesis of pulcherriminic acid by Bacillus subtilis”,J.Bacteriol 111(1):86-93, 1972. Van Dijl and Hecker,“Bacillus subtilis:from soil bacterium to super-secreting cell factory”,Microbial Cell Factories,12(3).2013. Vorobjeva et al.,FEMS Microbiol.Lett.,7:261-263,1980. Ward,“Proteinases,”in Fogarty (ed.).,Microbial Enzymes and Biotechnology.Applied Science,London,pp 251-317,1983. Wells et al.,Nucleic Acids Res. 11 :7911-7925,1983. Westers et al.,“Bacillus subtilis as cell factory for pharmaceutical proteins:a biotechnological approach to optimize the host organism”,Biochimica et Biophysica Acta., 1694:299-310,2004. Yang et al,J.Bacteriol.,160:15-21,1984. Yang et al.,Nucleic Acids Res.11:237-249,1983. Youngman et al.,Proc.Natl.Acad.Sci.USA 80:2305-2309,1983.

Claims

1. 1. An altered Bacillus licheniformis cell derived from a parent B. licheniformis cell that contains a native rghR2 gene, comprising: the modified cell comprises a modified rghR2 gene, the modified rghR2 gene comprising a genetic modification that mutates, disrupts, partially deletes, or completely deletes the 5'-UTR and / or 3'-UTR sequences of the rghR2 gene, the modified rghR2 gene does not express the encoded RghR2 protein; The modified cell produces a reduced amount of a red pigment compared to the parent cell when cultured under the same conditions.

2. 2. The modified cell of claim 1, wherein the red pigment is further defined as pulcherrimic acid.

3. 3. The modified cell of claim 1 or 2, comprising one or more expression cassettes encoding a protein of interest.

4. 4. The modified cell of claim 3, wherein the one or more expression cassettes encode an amylase protein.

5. The modified cell of any one of claims 1 to 4, wherein the modified cell produces an increased amount of a protein of interest compared to the parent cell.

6. 1. A method for producing a protein of interest in an engineered Bacillus licheniformis cell, wherein the engineered cell produces reduced amounts of a red pigment during fermentation, the method comprising: (a) obtaining a parent B. licheniformis cell and genetically modifying the rghR2 gene at the rghR locus; and (b) fermenting the modified cells under suitable conditions for producing the protein of interest; The modified rghR2 gene comprises a genetic modification that mutates, disrupts, partially deletes, or completely deletes the 5'-UTR sequence and / or the 3'-UTR sequence of the rghR2 gene, and the modified rghR2 gene does not express the encoded RghR2 protein; The modified cells produce a reduced amount of a red pigment compared to the parent cells when cultured under identical conditions.

7. The method of claim 6 , wherein the cells contain one or more expression cassettes encoding a protein of interest.

8. The method of claim 7 , wherein the one or more expression cassettes encode an amylase protein.

9. The method of any one of claims 6 to 8, wherein the modified cell produces an increased amount of the protein of interest compared to the parent cell when cultured under the same conditions.

Images